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The blood-brain barrier (BBB) is physiologically essential for brain homeostasis. 
While it protects the brain from noxious agents, it prevents almost all currently 
available drugs from crossing to the parenchyma. This greatly hinders drug delivery for 
the treatment of neurological diseases and disorders such as Parkinson’s, Alzheimer’s 
and Huntington’s, as well as the development of drugs for the treatment of such 
diseases. Current drug delivery techniques to the brain are either invasive and target 
specific, or non-invasive with low special specificity. Neither group of techniques are 
optimal for long term treatment of patients with neurological diseases or disorders. 
Focused ultrasound coupled with intravenous administration of microbubbles (FUS) 
has been proven as an effective technique to selectively and noninvasively open the BBB 
in multiple in vivo models including non-human primates (NHP). Although this 
technique has promising potential for clinical outpatient procedures, as well as a 
powerful tool in the lab, the safety and potential neurological effects of this technique 
need to be further investigated. This thesis focuses on validating the safety and efficacy 
of using the FUS technique to open the BBB in NHP as well as the ability of the 
technique to facility drug delivery. First, a longitudinal study of repeatedly applying 
the FUS technique targeting the basal ganglia region in four NHP was conducted to 
determine any potential long-term adverse side effects over a duration of 4-20 months. 
The safety of the technique was evaluated using both MRI as well as behavioral testing. 
Results demonstrated that repeated application of the FUS technique to the basal 
ganglia in NHP did not generate permanent side effects, nor did it induce a permanent 
 
 
opening of the BBB in the targeted region. The second study investigated the potential 
of the FUS technique as a method to deliver drugs, such as a low dose of haloperidol, to 
the basal ganglia in NHP and mice to elicit pharmacodynamical effects on responses to 
behavioral tasks. After opening the BBB in the basal ganglia of mice and NHP, a low 
dose of haloperidol was successfully delivered generating significant changes in their 
baseline motor responses to behavioral tasks. Domperidone was also successfully 
delivered to the caudate of NHP after opening the BBB and induced transient 
hemilateral neglect. In the final section of this thesis, the safety and efficacy of the FUS 
technique was evaluated in fully alert NHP. The FUS technique was successful in 
generating BBB opening volumes larger on average to that of the BBB opening volumes 
in anesthetized experiments. Safety results through MRI verification as well as 
behavioral testing during application of the technique demonstrated that the FUS 
technique did not generate adverse neurological effects. Conversely, the FUS technique 
was found to induce slight positive effects on the response of the NHP to the behavioral 
task. Collectively, the work presented in this thesis demonstrates the safety and 
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Introduction & Specific Aims 
1.1 Introduction 
The blood-brain barrier (BBB) is a highly selective biological system facilitating 
both brain homeostasis and prevention of noxious or infectious agents reaching the 
brain parenchyma [1]. As with many efficient systems, there is a downside as the BBB 
prevents 99% of currently available small molecules (> 400 Da), and almost all large 
molecule drugs crossing into the brain [2]. This creates a difficult challenge for the 
clinical treatment of neurological and psychiatric diseases based on existing or pipeline 
drugs [3, 4]. Current techniques for drug delivery through the BBB such as intracranial 
injection are invasive and localized while others methods employing endogenous 
transporters are non-invasive with nonspecific delivery [5, 6, 7]. With an estimated 6.4% 
of the world’s population expected to have a neurological disease or disorder by the 
end of 2015, there is a need for novel methods of treatment for diseases such as 
Alzheimer’s, Parkinson’s (PD) and Huntington’s *8]. An optimal system for drug 
delivery through the BBB would be non-invasive, have high spatial specificity and be 
reproducible without any permanent long-term side effects. 
 
Focused ultrasound coupled with intravenous (IV) administration of 
microbubbles (FUS) has been shown to be an effective method to open the BBB in 
multiple in vivo models for fourteen years [9, 10, 11, 12]. The FUS excites the circulating 
MB in the focal area of the transducer, resulting in the MB applying mechanical forces 
on the endothelial cells that form the BBB [13]. This technique is non-invasive and the 
opening of the BBB in the targeted region is reversible within hours to days tailored by 
the parameters employed [11, 14, 15]. Our group and others have shown the FUS 




anesthetized NHP [13, 15, 16]. The targeting of the brain structures can be achieved 
through either MRI guidance or stereotactical positioning [15, 16]. All in vivo 
applications of the FUS technique have been conducted with anesthetized animals [9, 
10, 11, 12, 13, 14, 15, 16, 17, 18, 19]. There has been no study to date investigating the 
potential neurological effects of applying the FUS technique on fully alert subjects. 
 
Although the FUS technique has been applied with multiple in vivo models, few 
studies have been conducted specifically investigating the safety of the technique on 
brain structure and function. One prior study investigated the safety of short-term 
repeated FUS BBB opening in the visual cortex of NHP and found minor damage with 
the parameters they used through T2-weighted MRI scans and from histological 
examination [16]. Aside from the short-term applications for treatment of tumors, the 
FUS technique in the clinic would be applied over multiple years. For treatment of 
neurological diseases such as PD and Alzheimer’s disease, specific brain regions may 
need to be repeatedly targeted to facilitate drug delivery. A longitudinal study applying 
the FUS technique to the striatum in mice revealed no long-term adverse effects [20]. 
While the results from these studies are positive, the safety of a long-term application of 
the FUS technique in NHP requires further investigation.  
 
Multiple groups have utilized the FUS technique to open the BBB facilitating 
treatment of brain tumors or to deliver therapeutic agents. To date, there have been no 
studies investigating drug delivery for eliciting a pharmacodynamical effect 
modulating behavioral responses to external stimuli [21, 22, 23]. Parkinson’s disease is a 
complex disease affecting many neurological functions with motor deficits being the 
most noticeable. Parkinson’s can also have neuropsychiatric effects causing difficulty 
with speech, decision-making, and memory [24, 25]. Potential drug therapies for PD 




cerebellum [26]. It is a necessity that the pharmacodynamic effects of drugs delivered 
via the FUS be investigated in NHP before clinical and laboratory applications can be 
implemented.  
 
The main goal of this dissertation is the evaluation of the safety and efficacy of 
the FUS technique in NHP. This goal was divided to three main objectives. The first 
investigated the safety and efficacy of the FUS technique when applied to anesthetized 
NHP over a duration 4-20 months (Chapter 3). Results from this study demonstrated 
that repeated application of the FUS to the basal ganglia in NHP did not have 
significant long-term effect on the targeted brain region, nor affect the responses of the 
NHP to a visuomotor task. Second, the FUS BBB opening technique was utilized to 
facilitate the delivery of haloperidol and domperidone to the basal ganglia in NHP and 
mice (Chapter 4). Successful delivery of the D2-antagonists resulted in 
pharmacodynamical modulation of the animals’ behavioral responses to visuomotor or 
simple motor tasks. The last objective demonstrated the safety and efficacy of the FUS 
technique in alert subjects by opening the BBB at the caudate, thalamus and putamen 
regions of fully alert NHP while they completed a visuomotor task (Chapter 5). Results 
from this study were the first to verify the technique can be successfully applied to fully 
alert subjects without eliciting negative side effects. 
 
Specific Aims 
1.2 Specific Aims 
 This thesis has three specific aims addressing the safety and efficacy of opening 
the BBB with FUS in NHP. A flowchart of the individual aims is shown in Figure 1. The 
first specific aim focused on determining if there were detectable physiological or 




anesthetized NHP. The second specific aim incorporated the results from the first 
specific aim and utilized the FUS technique to deliver D2 antagonist to the basal ganglia 
in NHP and mice. These two initial specific aims addressed the long-term effects, and 
the applicability of the FUS technique for drug delivery in anesthetized NHP. The third 
specific aim was necessary for pre-clinical translation of the technique and entailed 
applying the FUS technique to fully alert NHP investigating the safety and efficacy of 
the procedure. 
 
Figure 1. Specific Aims 
1.3 Longitudinal Study of the Effects from Focused Ultrasound 
Through the Microbubble-Mediated Blood-Brain Barrier Opening 
in the Non-Human Primate Brain (Specific Aim 1, Chapter 3) 
 The purpose of this aim was to investigate the potential side effects from 
applying the FUS technique to the basal ganglia in anesthetized NHP over a period of 4-
20 months. Specific aim 1 also developed analysis pipelines that would be implemented 




1. A brain region specific post-processing pipeline of MRI data for 
verification of BBB opening and safety of the procedure 
2. A behavioral analysis pipeline for evaluating the potential neurological 
effects of the FUS technique.  
To reach the goal of clinical application with the FUS technique, the removal of 
personal bias is required to achieve the same planning, and analysis of the procedure 
regardless of the user. The first section of specific aim 1 introduces a user-independent 
BBB opening analysis that produced results independent of personal interpretation.  
  For evaluation of neurological effects of chronic FUS procedures, and to 
determine the efficacy of drug delivery via BBB opening in specific aim 2, a behavioral 
analysis pipeline was created. The behavioral analysis pipeline was developed for two 
behavioral tasks, a reward magnitude bias (RMB) task and a RMB + random dot motion 
task (RDM). The behavioral analysis pipeline developed in specific aim 1 was 
implemented with all subsequent specific aims.  
Utilizing the opening verification and behavioral analysis pipelines, a 
longitudinal study of repeated FUS application in anesthetized NHP was conducted. It 
was hypothesized that chronic application of FUS in the basal ganglia would not have 
an effect on decision or motor responses when conducting a behavioral task after BBB 
opening, nor any permanent damage to the brain (edema, microhemorrhage). Results 
indicated that chronic (4 months minimum, 20 months maximum) FUS BBB opening in 
the putamen and caudate structures of the basal ganglia in three NHP did not induce 
any observable long-term effects on the recorded behavioral results. The majority of the 
FUS procedures were without any detectable edema or microhemorrhage on T2-
weighted or susceptibility weighted imaging (SWI). Overall, the results demonstrated 
the FUS technique is a safe and effective procedure for repeatedly opening the BBB in 





1.4 Drug Delivery to the Basal Ganglia via Focused Ultrasound with 
Microbubbles Blood-Brain Barrier Opening in Non-Human 
Primates and Mice (Specific Aim 2, Chapter 4) 
The goal of this specific aim was to determine the efficacy of both large molecule 
and low dose drug delivery to the basal ganglia region in the NHP and mice brains 
after opening the BBB with the FUS technique.  
One major benefit of opening the BBB at target specific regions is to allow large 
molecule drugs that normally cannot cross the native BBB to access the brain 
parenchyma. The FUS BBB opening technique could also be utilized to lower the 
administered dosage of currently available drugs that cross the intact BBB. Opening the 
BBB at the specific region of interest for drug effects could allow for the same desired 
therapeutic effect of a full dose of the drug with a lower chance of potential side effects 
[27]. Many neuroactive drugs have adverse side effects that could be reduced or 
negated with lower doses *28, 29+. This would greatly benefit Parkinson’s disease 
patients that require daily doses of levodopa by reducing the unwanted side effects 
such as dyskinesia [30].   
 The hypothesis was the FUS technique could allow for lower doses of drugs to 
reach specific brain regions and elicit similar behavioral responses as a full dose of the 
drug. Haloperidol and domperidone, two D2- antagonists, were selected as the drugs. 
The first part of this aim investigated the behavioral effects of low dose haloperidol on 
NHP and mice after opening the BBB in the putamen and caudate-putamen regions 
respectively. While haloperidol normally crosses the intact BBB, a threshold IM 
administered dosage (0.01mg/kg) that did not affect the behavioral results while the 
BBB was intact was determined and applied throughout the experiment. For both 
animal groups, there were significant changes in the results of behavioral testing with a 




when the BBB was intact. For the second part of this specific aim, domperidone, which 
cannot normally cross the BBB, was administered to four NHP after opening the BBB in 
the caudate. Two of the NHP displayed strong signs of hemilateral neglect, indicate that 
the domperidone had successfully crossed the BBB into the caudate. The drug delivery 
study in specific aim 2 confirmed that the FUS technique could be employed to deliver 
either large molecules or low drug dose to the basal ganglia and elicit 
pharmacodynamical effects on responses to behavioral testing. 
 
1.5  Safety and efficacy of Blood-Brain Barrier Opening via Focused 
Ultrasound with Microbubbles in Alert Non-Human Primates 
(Specific Aim 3, Chapter 5) 
Specific aim 3 determined the safety and efficacy of the FUS technique in alert 
NHP via MRI verification and behavioral testing. 
For the FUS technique to become an outpatient procedure in the clinic, as well as 
a non-invasive and time efficient technique for targeted drug delivery allowing 
pharmacodynamical behavior modulation in the lab, the safety and efficacy of the 
procedure in alert subjects needed to be verified. Some groups have reported 
neuromodulation in alert NHP and in humans using transcranial focused ultrasound 
(tFUS) without MB administration [31, 32]. To modulate brain activity, both groups 
used acoustic pressures up to two times larger than employed in this specific aim.  
The hypothesis was that the FUS technique would be both a safe and effective 
method to open the BBB in alert NHP. Results showed the average volume of BBB 
opening was slightly larger in alert compared to anesthetized animals. There was also a 
decrease in the occurrence of edema for the alert FUS procedures compared with the 
anesthetized procedures. Behavioral testing revealed a small non-significant decrease in 




significant decrease in touch error while the sonication was occurring suggesting the 
technique could provide a small beneficial effect to motor function when targeting the 



























Background & Motivation 
2.1 Blood-brain barrier  
The blood brain barrier (BBB) is a selective barrier comprising of the tight 
junctions between endothelial cells that line the cerebral vasculature [33]. Figure 2 
shows an illustration of the BBB and surrounding neuronal cells. This barrier controls 
the influx and efflux of molecules and nutrients from the lumen to the parenchyma 
enabling brain homeostasis for neuronal activity [34, 35]. The tight junctions between 
endothelial cells act as a physical and metabolic barrier excluding molecules with a 
molecular weight greater than 400-600 Da that are not lipid soluble [4, 36]. The only 
other means of transport across the native BBB is through paracellular or transcellular 
pathways [37]. Due to the selectivity of the BBB, 99% of small molecule and almost all 
large molecule drugs and molecules (proteins, enzymes) cannot cross the intact BBB 
[38]. The selectivity of the BBB prevents many drugs from being utilized as therapeutic 





Figure 2: The Blood-Brain Barrier. Capillary endothelial cells lining the vasculature form tight 
junctions between cells bound by proteins creating a diffusion barrier. The astrocyte feet 
processes are critical for this tight junction upkeep. (Source: Netter’s Atlas of Human Anatomy, 
1st edition) 
2.2 Current Blood-Brain Barrier Disruption and Drug Delivery 
Techniques 
Due to the BBB being a limiting factor for the treatment of most neurological 
diseases and disorders, multiple techniques have been developed to circumvent it. 
These techniques include modifying the composition of the drugs to facilitate uptake 




procedures [38, 42] and using chemical, biological or physical mechanisms to open the 
BBB and deliver the drug [43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53].  
2.2.1 Drug Modifications 
The characteristics of some drugs can be modified to increase the delivery efficiency 
across the BBB. These characteristics include the molecular weight, permeability as well 
as solubility. As mentioned in section 2.1, drugs need to be lipid soluble to cross the 
BBB, hence one of the main drug modification techniques is ‚lipidization.‛ This process 
converts non-polar functional groups into polar groups increasing the ability of the 
drug to cross the BBB [40]. Modifying the drugs to target endogenous transport is 
another technique to increase drug permeability across the BBB [39]. The two main 
common techniques include carrier-mediated transport (CMT) and receptor-mediated 
transport (RMT). The implementation of these techniques is dependent on the specific 
drug being transported across the BBB. CMT is designed to transport hormones, 
nutrients and proteins across the BBB. Small molecules with MW < 600 Da that can 
modify their structure to mimic commonly transported molecules such as glucose or 
neutral amino acid are prime candidates for utilizing CMT to deliver drugs across the 
BBB [41]. If the drug molecule is too large, RMT could be utilized by modifying the 
drug to bind to the insulin receptor, insulin-like growth factor receptor or the 
transferrin receptors. This utilizes the endocytotic processes to deliver the drug to the 
brain parenchyma [54, 55].  
The limitation of these drug modification techniques is that only a certain amount of 
drugs are able be modified to fit transport criteria, and the delivery through the BBB is 





2.2.2 Invasive Techniques 
Invasive procedures include direct transcranial or intraventricular injections with 
pump infusions as well as convection-enhanced delivery [38, 42]. These techniques 
allow for precise delivery of the drug to the region intended for brain-drug interaction.  
The main invasive technique is transcranial injection that may be either intracerebral 
or intracebroventricular. These are the current gold standard for invasive drug delivery 
to the brain as the full dose of the drug is delivered to the intended region for brain-
drug interaction [57]. The limitations with this technique are that the treatment area is 
constrained by the diffusion of the drug (usually only a few millimeters around the 
injection location) and backflow of the drug into the needle and path of the needle 
during removal can reduce drug delivery efficiency [38]. 
Convection-enhanced drug delivery is another invasive technique and as with the 
transcranial injections physically bypasses the BBB with a catheter. Here the drug is 
delivered via positive hydrostatic pressure for infusion of the drug to the targeted 
region allowing a larger treatment area than with the transcranial injections [58]. Due to 
the use of the hydrostatic pressure, drug delivery efficiency is also increased over 
transcranial injections. 
The major limitations for the two invasive techniques are that they require surgical 
procedures that have the potential for adverse complications and some patients may 
not be good candidates for sedation with anesthesia. Structural damage to the brain due 
to either the needle or catheter placement for the delivery of drugs is also a drawback 






2.2.3 Non-Invasive Techniques 
Numerous non-invasive methods have been developed for opening the BBB for 
drug delivery. These are divided into three groups; chemical, biological and physical. 
These techniques primarily disrupt the BBB, increasing the permeability of the barrier 
and allowing the drugs to be administered via traditional methods (orally, IV) and 
achieve successful therapeutic doses in the brain parenchyma. 
Chemical techniques to open the BBB include administration of solvents such as 
Dimethyl Sulfoxide (DMSO), or surfactants such as sodium dodecyl sulfate (SDS) and 
Tween 80 [43, 44, 45]. The mechanism of increasing the BBB permeability with the 
DMSO technique involves disrupting the tight junctions between the endothelial cells 
that comprise the BBB [43]. Administering SDS or Tween 80 modifies protein kinase C 
(PKC) signaling in the endothelial cells that comprise the BBB [44, 45]. PKC is associated 
with the regulation, assembly and permeability of the tight junctions formed by the 
endothelial cells lining the cerebral vasculature [59]. This modulation of the PKC 
signaling increases the permeability of the BBB allowing for drugs to diffuse across into 
the brain parenchyma.  
Biological techniques employ mannitol, adeno-associated viruses (AAV), 
interleukin-1 β, and RMP-7 to open the BBB as well as drug loaded macrophages and 
peptides as a Trojan horse drug delivery method [46, 47, 48, 49, 50, 60].  Mannitol is the 
most widely studied method of opening the BBB and functions by shrinking the 
endothelial cells and opening the tight junctions [46]. Both the AAV and interleukin-1 β 
method utilize cytokines which trigger an immune response to the location of delivery 
inducing a breakdown of the BBB [47, 60]. RMP-7 functions more similar to the 
chemical solvents as it opens the tight junctions between the endothelial cells lining the 




macrophages that can freely cross the BBB to deliver the drug into the brain 
parenchyma [49]. The macrophage method is most advantageous for treatment of 
neurological diseases that would incur an immune response and has been shown 
successful for treating HIV. Peptides, short amino acids chains with the ability to pass 
through lipid bilayers, are ideal for delivering biologically active molecules as they are 
positively charged and highly lipid-soluble [48, 63, 64]. Multiple peptides have been 
shown successful as a method for drug delivery to the brain, but the most successful 
ones are the most lipophilic which was discussed as a drug delivery technique in 
section 2.2.1. 
Physical techniques to open BBB include using microwave, electromagnetic fields 
and ultrasound [51, 52, 53]. The microwave technique utilizes placement of an antenna 
in the skull operating at 2450 MHz and induces hyperthermia (44.3 ˚C for 30 minutes) at 
targeted regions [51]. This hyperthermia induces BBB openings in the targeted regions 
[65].  The electromagnetic fields method employs high voltage (200 kV/M) EMP pulses 
to activate the PKC signaling in the endothelial cells lining the cerebral vasculature, 
similar to the chemical surfactant method [52, 66].  This activation of the PKC signaling 
produced significant BBB opening after 3 hours. The ultrasound method utilizes 
microbubbles, an ultrasound contrast agent, coupled with a focused ultrasound 
transducer to accurately target specific brain regions for BBB opening [53, 67]. This 
technique will be covered more thoroughly in sections 2.2.1  
The limitation with the majority of the aforementioned non-invasive chemical, 
biological and physical techniques are that they are primarily non-target specific. While 
both the physical techniques provide some special specificity, the microwave radiation 
requires the antenna be drilled into the skull, while the electromagnetic fields can only 
target a large area (30 x 30 cm) [51, 52]. The only technique to open the BBB that 





Clinical ultrasound has two main applications, diagnostic and therapeutic. Both 
applications utilize transducers, a device containing at minimum one piezoelectric 
component that produces acoustic pressure waves when voltage is applied [68]. These 
waves then propagate through the tissue resulting in some waves being absorbed and 
some reflected back to the transducer where either a different, or the same piezoelectric 
component detects the reflected waves and converts them to voltage for either visual 
interpretation or data analysis [68]. 
Diagnostic ultrasound typically employs B-mode, M-mode or Doppler for 
imaging target areas within patients such as fetuses. It can also be used to image heart 
motion and blood flow [69, 70, 71]. Transducers employed for diagnostic purposes 
typically operate with higher frequencies ranging between 2-12 MHz, have a short duty 
cycle (fraction of time when the transducer emits the acoustic wave relative to the full 
duration of the procedure) and lower acoustic pressures resulting in overall lower 
acoustic intensities (1.0 W/cm2 or less). These parameters reduce the potential of 
damage to the tissue being imaged.  
Therapeutic ultrasound utilizes specialized transducers that typically operate at 
higher intensities and lower frequencies. The acoustic waves generated from these 
transducers can cause two different effects, thermal and non-thermal [72]. Thermal 
effects occur with high duty cycles or continuous wave ultrasound in conjunction with 
higher acoustic pressures. These parameters cause the temperature of the targeted 
tissue to increase and can cause the tissue to become thermally ablated. Therapeutic 
ultrasound techniques that utilize thermal effects include high intensity focused 
ultrasound (HIFU) and lithotripsy [73, 74]. HIFU is utilized to ablate tissue while 




The non-thermal applications utilize transducers with lower duty cycles and 
lower frequencies around 0.5-1.5 MHz, but similar high acoustic pressures. Multiple 
therapeutic ultrasound techniques utilize non-thermal effects such as sonoporation, 
histotripsy and FUS mediated BBB opening [53, 75, 76]. The main non-thermal effect is 
cavitation, or the generation of microbubbles from nucleation sites in the tissue where 
small pockets of gas exist, and the interaction of the generated microbubbles with the 
acoustical waves [77, 78]. These microbubbles can oscillate and grow within the acoustic 
waves and have the potential to implode. The generation and manipulation of these 
bubbles can lead to different therapeutic effects. Sonoporation generates temporary 
pores in cell membranes induced by ultrasound to facilitate the uptake of specific drugs, 
while histotripsy utilizes cavitation to non-thermally destroy tissue [75, 76, 79, 80]. FUS 
mediated BBB opening utilizes cavitation as a mechanism to open the BBB, but in a 
safer, more controlled method by administering ultrasound contrast agent 
(microbubbles) before sonicating the target regions [53]. This allows for the disruption 
of the BBB with minimal damage depending on the parameters employed.  
2.3.1 Focused Ultrasound with Microbubbles 
Multiple groups have utilized FUS with systemically administered microbubbles 
(MB) to open the BBB with in vivo animal models such as rabbits, mice, pigs, and non-
human primates (NHP) [9, 10, 11, 12]. The FUS is an acoustic transducer comprised of a 
piezoelectric element which when driven with an electric current, generates an acoustic 
pressure wave. This acoustic wave is able to propagate through the skin, skull and 
tissue, enabling the targeting of subcortical regions of the brain [15, 19]. The focal area 
of the FUS has an inverse relationship to the center frequency of the FUS. As the center 
frequency increases, the focal area decreases. Combining the application of FUS with 
systemically administered MB for BBB opening is unique as it allows for target specific 




Acoustic waves from the FUS transducer interact with the circulating microbubbles at 
the focal zone and cause short-term disruption of the tight junction complexes between 
the endothelial cells that form the BBB [84]. The FUS technique has been shown effective 
in NHP and mice over a range of ultrasound parameters and MB sizes [13, 15, 16].  
2.3.2 Cellular Mechanisms of Blood-Brain Barrier Opening 
The exact mechanism of BBB opening is unknown, but acoustic cavitation of the MB 
in the focal area of the FUS has been determined as a major factor [36]. The two central 
components of the acoustic cavitation have been identified as stable and inertial 
cavitation (Figure 3) [85, 86]. Stable cavitation is comprised of both harmonic and 
ultraharmonic oscillations of the MB and has been reported to be safe for in vivo animal 
models [15, 17, 87]. Inertial cavitation is defined as the broadband signal from the MB in 
the focal area of the FUS [17]. Inertial cavitation usually occurs at higher acoustic 
pressures generated by the FUS transducer and causes the MB to collapse violently [88]. 
These collapses have been correlated with create high-energy microjets, which can 
cause damage to the surrounding tissue (Figure 2 B) [85, 88]. The interactions of the MB 
on the vascular walls are also dependent on the size of the MB and the diameter of the 
vessels [88]. If the MB is smaller than the surrounding vessel, then inertial cavitation is 
the dominant mechanism. If the MB and the diameter of the vessel are comparable, then 
stable cavitation is the dominant mechanism for BBB opening. The BBB opening from 
the FUS technique is transient and closes between 3 and 72 h depending on the 





Figure 3: Microbubble-Focused Ultrasound Interactions. A) Illustrates the two dominant 
mechanisms of microbubble oscillation within the focal area of the focused ultrasound beam: 
inertial and stable cavitation. B) Shows a microbubble undergoing inertial cavitation resulting in 
the formation of a microjet next to the vessel wall. (Sources: (A) Lentacker I et al. Soft Matter, 
2009, (B) Chen H. et al. PRL, 2011) 
2.3.3 Monitoring and Assessment of Blood-Brain Barrier opening 
As mentioned in chapter 2.2.2, microbubble cavitation is the main mechanism for 
BBB opening. The acoustic emissions from this cavitation can be monitored through 
passive cavitation detection (PCD). The acoustic emissions from the bubbles are 
detected with a hydrophone and the signals processed to determine the stable and 
inertial cavitation doses [18, 86, 87]. This study utilized real-time PCD to verify the 
microbubble dose was administered correctly and had reached the focal area of the FUS 




Figure 4: Passive Cavitation Detection. The acoustic emissions from the MB are constantly 
monitored throughout the application of the FUS technique. There is typically a 10-second lag 
before the harmonic signal increases past baseline. This is the time period of the MB being 
injected and circulating before reaching the focal area of the FUS. 
The blood-brain barrier opening is currently verified using three imaging 
modalities, SPECT/CT, microscopy and MRI [15, 89, 90]. The only method of the three 
to verify BBB opening in vivo with both high spatial and temporal resolution is MRI. 
The MRI can also provide functional and anatomical information that the other 
modalities cannot. Contrast enhanced T1-weighted MRI sequences can indicate the 
location of the BBB opening and is the most common technique for BBB opening 
verification [9, 13, 14, 15, 16]. Gadodiamide, a contrast agent with a molecular weight 
(MW) of 573.66 Da that normally cannot cross the BBB is typically utilized as an 
indicator of BBB opening. If the FUS procedure was successful and the BBB was opened, 
the contrast agent will cross into the brain parenchyma. The area where the contrast 
agent crossed increases the intensity of the voxels for T1-weighted MRI sequences 
indicating the area of BBB opening. This contrast-enhanced area is then quantified in 
post-processing to determine the volume of opening [15]. T2-weighted and 
Susceptibility Weighted Imaging (SWI) can be used to detect damage such as edema, 




indicate edema, while abnormal hypointense voxels on the SWI scans can indicate 
microhemorrhage [91, 92]. MRI analysis is an important multifunctional tool as other 
methods of measuring potential damage such as histology require the subject to be 
sacrificed.  
2.4 Drug Delivery via Focused Ultrasound with Microbubbles  
2.4.1 Treatment of Neurological Diseases 
As previously mentioned current methods of drug delivery across the BBB are 
either non-invasive and non-specific, or target specific requiring an invasive procedure 
[38, 81, 82]. The FUS technique for BBB opening is a promising technique for facilitating 
drug delivery that combines the positive attributes from current drug delivery 
modalities. The FUS technique has been shown to allow the delivery of various 
molecules across the BBB including therapeutic antibodies (Anti-αβ antibodies, 
endogenous antibodies, Herceptin), anti-cancer drugs (Cytarabine, Doxorubicin, 
Trastuzumab), Adeno-Associated Virus (AAV), nanoparticles, neurotrophic factors 
(BDNF, GDNF), and neural stem cells [21, 22, 23, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 
103, 104]. While delivery of these molecules only occurs with an open BBB, it is 
unknown if a drug that normally crosses the native barrier can elicit similar 
pharmacodynamical results at a lower administered dose when the barrier opened.  
2.4.2 Pharmacodynamical Behavior Modulation 
To this date, investigation using FUS BBB opening as a method for delivering 
neuroactive drugs that can modulate naive brain behavior to external stimuli (visual, 
auditory, tactile cues) has not been reported. There has been one study opening the BBB 
in the somatosensory cortex in rats with successful delivery of GABA while monitoring 




somatosensory evoked potential amplitudes where the BBB had been successfully 
opened. This study only investigated the neural activity and did not test how the 
suppression effected processing of external stimuli since the rats were anesthetized. In 
this thesis, the potential of the FUS technique be utilized for targeted drug delivery 
allowing pharmacodynamical behavior modulation was investigated. This was an 
important facet to explore as many neurological diseases such as Parkinson’s and 
Alzheimer’s disease affect the sensory-motor functions of the brain and how the patient 
reacts to external stimuli [25].  
2.5 Targeted Brain Regions 
2.5.1 Basal Ganglia 
The basal ganglia is a collection of subcortical nuclei situated at the base of the 
forebrain. It is has been implicated in various functions such as voluntary motor and 
eye movement control, as well as procedural, cognitive and emotional learning [106, 
107, 108]. Motor signals initiating from the motor cortex pass through the basal ganglia 
and the cerebellum before continuing to the spinal cord. The dorsal parts of the caudate 
and putamen are associated with sensorimotor while the ventral parts are associated 
with the limbic processing [108]. It has been proposed the basal ganglia plays a role in 
the activation of learned motor functions in the cerebral cortex [109]. Thus neurological 
diseases and disorders that disrupt the basal ganglia, such as Parkinson’s disease, 
typically manifest motor deficits. Parkinson’s disease affects the basal ganglia by 
causing degeneration of the dopamine-producing cells in the substantia nigra pars 
compacta [25]. This degeneration affects the other subcortical nuclei such as the 
putamen and caudate which can lead to motor impairment if dopamine levels decrease 
[110]. This motor impairment can be mimicked by injecting D2 antagonists into the 




prevents the inhibition the indirect pathway between the striatum and the substantia 
nigra [111]. The caudate nucleus is also implicated in voluntary motor control as well as 
other cognitive functions such as goal-directed action, memory and learning [109, 112, 
113]. As FUS could potentially be used as a tool for drug delivery treatment of PD, the 
putamen and caudate regions of the basal ganglia were selected as target regions for the 
studies in this thesis. The locations of these subcortical nuclei are indicated in Figure 5. 
2.5.2 Thalamus 
 The thalamus is located in the forebrain and facilitates signaling from the sub-
cortical structures to the cerebral cortex [114]. Similar to the basal ganglia, the thalamus 
region of the brain has been implicated with visuomotor activity as well as motivation 
[115, 116, 117+. Parkinson’s disease also affects the thalamus causing neurodegeneration 
in the region of the thalamus that provides feedback to the putamen [118, 119]. Damage 
to this region can impair awareness, cognition and perception. The thalamus was also 
selected as a target region for the FUS technique in this thesis as it also plays a critical 





Figure 5: Targeted Brain Regions in the NHP. The color-masked regions indicate the brain 
targets selected for the experiments conducted in this thesis. (Source: University of Wisconsin-
Madison Brain Collection) 
2.6 Behavioral Tasks 
2.6.1 Reward Magnitude Bias 
 The well-established reward magnitude bias (RMB) paradigm is suitable for 
testing motivation and decision-making [120]. The RMB task in its simplest form 
consists of two discriminable visual cues, one stimulus of which is worth more reward 
than the other stimulus. If the task requires a saccadic eye movement or manual reach, 
the reaction times between the two conditions can be compared. Prior studies 
implementing this paradigm have reported significantly faster reaction time to the high 
reward [121]. The RMB paradigm has been used to test motivation with a visually 




intracranial injections of D1 and D2 antagonist into the caudate [120]. This RMB 
paradigm was implemented in behavioral tasks throughout all the specific aims of this 
thesis, testing the visual perception, motivation and motor functions of the NHP. 
2.6.2 Random Dot Motion  
 The random dot motion (RDM) task is effective for evaluating decision-making 
and accuracy of responding to the correct target indicated by direction of moving dots 
[122, 123]. The task assesses the subject’s visual acuity and decision making by ranging 
the speed of dots moving in one coherent direction, or varying the amount of dots 
moving in one coherent direction [123, 124]. After presentation of the dots, the subject 
must decide between two response targets that correlate either for the speed, or the 
coherent direction of the dots. For the behavioral tasks employed in this thesis, the 
coherent motion of the dots was implemented. This means a percentage of the dots 
presented will move towards the correct target, while the remaining percentage of dots 
move randomly. Results from the RDM task provides the threshold level for correctly 
discerning the coherent direction of the dot motion. As both the basal ganglia and 
thalamus regions are implicated with visuomotor pathways, the RDM task was well 
suited to test for potential neurological changes after applying the FUS procedure to 










Specific Aim 1 
Longitudinal Study of the Effects from Focused Ultrasound 
Through the Microbubble-Mediated Blood-Brain Barrier 
Opening in the Non-Human Primate Brain 
 As discussed in chapter 2, prior short-term studies have been conducted 
investigating this topic, but to date no investigations have explored the potential 
neurological side effects from chronic applications of the FUS technique to a specific 
brain region. The first specific aim of this thesis addresses that question by verifying the 
safety and efficacy of long-term application of the focused ultrasound with microbubble 
technique to the basal ganglia in non-human primates.  
3.1 Abstract 
Focused ultrasound (FUS) coupled with intravenous administration of 
microbubbles (MB) is a non-invasive technique that has been shown to reliably open 
(increase the permeability of) the blood-brain barrier (BBB) with multiple in vivo models 
including non-human primates (NHP). This procedure has shown promise for clinical 
and basic science applications, yet the safety and potential neurological effects of long-
term application in NHP requires further investigation under parameters shown to be 
efficacious in that species (500kHz, 200-400 kPa, 4-5µm MB, 2 minute sonication). In this 
study, the BBB was repeatedly opened in the caudate and putamen regions of the basal 
ganglia of 4 NHP using the FUS technique over 4 – 20 months. The safety of the FUS 
technique was assessed using MRI to detect edema or hemorrhaging in the brain. 




in the targeted regions. T2-weighted and SWI sequences indicated a lack edema in the 
majority of the cases. The potential of neurological effects from the FUS technique were 
evaluated through quantitative cognitive testing of visual, cognitive, motivational, and 
motor function using a random dot motion task with reward magnitude bias presented 
on a touch panel monitor. Reaction times during the task significantly increased on the 
day of the FUS procedure. This increase returned to baseline within 4-5 days after the 
procedure. Visual motion discrimination thresholds were unaffected. The results 
indicate FUS with MB can be a safe method for repeated opening of the BBB at the basal 
ganglia in NHP for up to 20 months without any long-term negative physiological or 
neurological effects with the parameters used.  
3.2 Introduction and Study Design 
Our group and others have shown focused ultrasound with microbubble is an 
effective technique to open the BBB for multiple in vivo animal models [9, 10, 11, 12]. 
FUS is a promising technique for targeted drug delivery in the central nervous system, 
but before clinical application of this technique in humans can occur, the long-term 
effects of the technique on behavioral and cognitive function must be further 
investigated. 
The introduction of MB coupled with lower-pressure FUS has been shown not to 
damage tissue or cause neurological deficits in mice [13, 20]. Our group and others have 
shown that for specific parameters the FUS with MB procedure can be safe for non-
human primates [15, 16]. The primary method of evaluating potential damage from FUS 
BBB opening in NHP is MRI, specifically T2-weighted and Susceptibility-Weighted 
Imaging (SWI) scans [12]. There has been one study utilizing histological evaluation of 
the FUS BBB opening procedure in NHP over a period of 2-26 weeks [16]. While MRI 




method can detect if the FUS with MB procedure has an effect on neurological function. 
The same study reported the effects of several weeks of FUS with MB application on the 
thalamus (lateral geniculate nucleus) in the NHP model using a visual acuity task [16]. 
To date there has not been any study conducted on the neurological effects on motor 
and cognitive processing of repeated (> 13 months) FUS procedures with BBB opening 
in NHP.   
In this study, the effects of repeatedly applying FUS to the basal ganglia of four 
NHP over periods ranging from 4 to 20 months was investigated. Acoustic pressures for 
the FUS procedure were varied through the initial part of the experiment to determine 
safe ranges of these parameters in the basal ganglia. Within the basal ganglia, the 
caudate and putamen regions were selected as targets for FUS BBB opening as they are 
both implicated in voluntary motor control, goal-directed action, memory, learning, and 
decision-making, and are affected in Parkinson’s Disease *24, 25, 125]. The FUS with MB 
procedure was applied to NHP under general anesthesia using a stereotaxic targeting 
system. Constant monitoring of vital signs (respiration, blood pressure, heart rate and 
blood oxygenation levels) before, during, and after the FUS procedure was used to 
evaluate any potential physiological changes from repeated procedures. Following each 
FUS procedure, the safety of the procedure (lack of edema or hemorrhage) was 
evaluated with T2-weighted MRI and SWI sequences. The BBB opening was verified 
with contrast enhanced 3D T1-weighted MRI sequences. The safety of the FUS with MB 
procedure was also investigated with behavioral assessment using a reaching task 
based on a combination of a reward magnitude bias (RMB) paradigm and a random dot 
motion (RDM) task [120, 131, 122]. This combined task tested visual perception, 
decision-making, motivation and motor function to determine if the BBB opening 




evaluation coupled with the MRI results established a multi-faceted approach for 
verifying safety of long-term FUS BBB opening in NHP.  
3.3 Materials and Methods 
Subjects and Ethics Statement 
All NHP procedures described herein were approved by the Institutional Animal 
Care and Use Committees of Columbia University and the New York State Psychiatric 
Institute. Adult male macaques (n=4) were used in all experiments (ages 8-20 years, 
weights 5-9 kg); one Macaca fascicularis (NHP A) and three Macaca mulatta (NHP O, 
Ob, N). The NHP were housed (N & O were paired with each other) in a room with a 12 
hour light dark cycle. NHP were housed in a 3 ft3 Erwin-Steffes Enhanced 
Environmental Housing System (Primate Products Inc., Immokalee, FL, USA) and given 
access to play cages (total area 3 ft2 x 7 ft) with various enrichment toys (wooden food 
logs, plastic chew stars, mirror balls). They were fed constant rations of vitamin 
enriched dry primate biscuits and given 1L of water on days when they were not tested 
behaviorally. On testing days, the NHP performed the behavioral task for water reward 
until they were satiated. NHP were not given additional fluids even if they did not 
work for a full liter as supplementing the water they received from working with ‘free’ 
water would reduce their motivation to perform the behavioral task. Each day, after the 
behavioral session was completed, they were given a fruit treat.  
For each FUS with MB procedure, NHP were initially sedated with ketamine (10-
12 mg/kg) and given a dose of atropine (0.04mg/kg). An endotracheal catheter was 
inserted, after which the NHP were anesthetized with isoflurane (1-2%) mixed with O2 
(2 L/min) for the duration of the procedure. A stereotactic frame (David Kopf 
Instruments, CA, USA) was used for head fixation to ensure accuracy of the FUS 




reduce interference with the acoustic transmission. A catheter was placed in the 
saphenous vein for IV delivery of 0.9% saline, MB and the MRI contrast agent 
gadodiamide (Omniscan, 573.66 DA, GE, Healthcare, Princeton, NY, USA). A heated 
water blanket was used to maintain body temperature during the FUS with MB 
procedure. Heart rate (EKG), blood oxygenation (SpO2), end-tidal CO2 expiration, 
respiratory rate, and non-invasive blood pressure were recorded during the procedure. 
Five time-points were used for analysis of the vitals: immediately after the NHP was 
placed in the stereotax, 30 seconds prior to MB injection, 60 seconds into the sonication, 
30s after sonication, and the last point at the end of the procedure when the NHP was 
taken out of the stereotax.   
FUS with MB procedure 
All MB used in the procedure were made in-house and centrifuged for size 
isolation with a mean MB diameter of 4-5µm [126]. A 500-kHz center frequency focused 
ultrasound transducer was used for all experiments (H-107, Sonic Concepts, WA, USA). 
The built-in water bladder system on the transducer was filled with de-ionized water 
and circulated through a degasser (Sonic Concepts, WA, USA) for a minimum of 30 
minutes before the FUS with MB procedure. Acoustic pressures ranging from 200-400 
kPa were applied with a pulse length of 10ms, pulse repetition frequency of 2 Hz with a 
total sonication duration of 2 minutes per target location. The caudate and putamen 
regions of the basal ganglia were selected as the two main targeting regions. A detailed 
list of acoustic pressures and targeted locations for each NHP are located in Table 1. The 
transducer was mounted on a 9-degrees-of-freedom stereotactic arm (David Kopf 
Instruments, CA, USA) that was attached to the stereotactic frame securing the head of 
the NHP. Stereotactic coordinates were found with an in-house targeting algorithm 
calibrated for the focal distance of the transducer [15]. An initial six-second sonication 




injection of MB with a concentration of 2.58 MB/kg was used for each initial sonication. 
The FUS procedure was initiated at the onset of IV MB injection with an average 
circulation time of 10s before MB reached the focal area. Real-time monitoring via a 
hydrophone (Y-107, Sonic Concepts, WA, USA) was used to verify that MB had reached 
the focal zone and to monitor harmonic, ultraharmonic and inertial cavitation levels 
[18]. The hydrophone was placed through a center hole in the FUS transducer allowing 
overlap of their focal regions. A pulse generator (Olympus, PA, USA) drove the initial 
signal which was passed through a 20-dB amplifier (5800, Olympus NDT, MA, USA) 
providing the signal to the transducer. Output from the hydrophone was filtered 
through a pulse-receiver (5072PR, Olympus, PA, USA) before being digitized (Gage 
Applied Technologies, Inc., Lachine, QC, Canada) and recorded. For some experiments 
(n = 31), a second sonication was conducted < 1 min after first sonication at an area 
adjacent (average 1.5 cm shift on anterior-posterior axis) from the initial sonication 
location, but still within the same targeted subcortical nuclei. For those sonications, real-
time monitoring verified that MB remained in circulation and had not yet been filtered 
out, thus a second injection of MB was not necessary. If the caudate and the putamen 
were both sonicated on the same day, a 20-min waiting period occurred between 
sonications allowing the MB to be filtered from the bloodstream. Once the 20 minutes 
passed, another negative control was acquired to verify the MB had been filtered before 








Table 1. Targets and acoustic pressures of FUS with MB procedures for each NHP. 
NHP Brain Target Acoustic Pressures (kPa) Duration 
A L. Putamen 300 (n = 12) 10 mo* 
N L. Putamen 200 (n = 1), 275 (n = 8)  11 mo 
N R. Putamen 400 (n = 9)  10 mo* 
N L. Caudate 250 (n = 6), 300 (n = 3)  12mo 
O L. Putamen 250 (n = 4), 275 (n = 6)  12 mo 
O L. Caudate 200 (n = 4), 250 (n = 3), 275 (n = 1)  20 mo 
Ob L. Putamen 400 (n = 4) 4 mo* 
The n indicates the number of time FUS was applied to that region at that pressure. The 
duration was the amount of time over when the FUS with MB procedures occurred. Asterisk 
durations indicate time while completing RDM + RMB task. 
MRI Analysis 
MRI scans (3T, Philips Medical Systems, MA, USA) for each NHP were acquired 
either 30 minutes (n = 36) or 30 hours (n = 25) after the FUS with MB procedure. T2-
weighted sequences (TR = 10ms, TE = 27ms, flip angle = 90°, spatial resolution = 400 x 
400 µm2, slice thickness = 2mm with no interslice gap) and 3D Susceptibility-Weighted 
Image (SWI) sequences (TR = 19ms, TE = 27ms, flip angle = 15°, spatial resolution = 400 x 
400 µm2, slice thickness = 1 mm with no interslice gap) were used to verify safety of the 
procedure. 3D Spoiled Gradient-Echo (SPGR) T1-weighted sequences (TR = 20ms, TE = 
1.4ms, flip angle = 30°, spatial resolution = 500x 500 µm2, slice thickness = 1 mm with no 
interslice gap) were acquired after IV administration of gadodiamide at a dose of 0.2 
ml/kg to confirm BBB opening. Gadodiamide was selected as the contrast agent as it 
does not cross the intact BBB. There was a 30-min diffusion period after IV 




acquired. On a separate day when the BBB was not open (no FUS with MB procedure 
for > 1 week), another contrast enhanced T1-weighted sequence was acquired for post-
processing purposes (T1-Gado). Each T1-Post sequence was post-processed to find the 
opening location and the volume of the induced BBB opening (Figure 6). The T1-Post 
and T1-Gado sequences were aligned to a high-resolution stereotaxically oriented T1-
weighted sequence for each NHP with the FSL toolbox (Figure 6 B) [127]. A grey and 
white matter segmentation map of each brain was generated and used to find the 
average voxel intensity of the grey and white matter for image normalization of the T1-
Post and T1-Gado sequences (Figure 6 C). Subsequently, the normalized T1-Post was 
divided by the normalized T1-Gado to locate of voxels where the contrast was increased 
over baseline (Figure 6 D). The focal area was determined and all voxels that had a 
contrast increase of 10% within the focal region were counted to determine the volume 
of the BBB opening (Figure 6 E). The center of the opening was found by weighing each 
voxel above the threshold with its intensity and then averaging all weighted voxel 
locations. Contrast enhanced T1-weighted MRI scans were also acquired at least one 
week after any FUS with MB procedures at the midpoint and after the final FUS with 
MB procedure for each animal. These scans were processed using the aforementioned 





Figure 6: Blood-Brain Barrier Opening Post-Processing Pipeline. A) Initial raw contrast 
enhanced T1-weighted image (T1-Post). B) Stereotactically aligned and smoothened image 
constructed from A. C) Grey white segmentation map created from B. D) Contrast enhanced 
results from dividing normalized T1-Post by normalized T1-Gado. E) Contrast enhanced result 
after applying focal area thresholding. 
 
Behavioral Testing 
Three of the NHP (A, N, Ob) were trained to touch visual stimuli presented on a 
20-inch color LCD touch panel monitor (NEC 2010X with 3M SC4 touch controller, 
Figure 7). Each successful trial was rewarded with 1 or 5 drops of water delivered 
through a spout positioned in front of the mouth. Daily sessions ranged between 1- 3 
hours during which the NHP would typically perform 700-2000 trials of the task and 
receive 100-400 ml of fluids. At the start of each session, the NHP was placed in an 
IACUC-approved chair in which their head and both hands were free to move. A 




reaching across the display. Thus, stimuli presented on the right side of the monitor 
were only accessible to the right hand, and likewise for the left side.  
The reaching task combined the well-established Random Dot Motion detection 
paradigm (RDM) with a Reward Magnitude Bias (RMB) [121, 122, 123]. The combined 
task tested reaction time (RT), touch error (TE), motivation and decision-making. For 
each trial an initial cue, a horizontal or vertical yellow bar was presented randomly on 
either the left or right side of the screen (the pixel area and intensity was the same for 
both orientations). A horizontal bar signified a large reward of five drops of water while 
a vertical bar signified a small reward of one drop of water (5:1 reward bias). Previous 
studies implementing a RMB paradigm have used smaller reward differentials, but a 
larger bias was selected to make the difference more salient to the animals and thereby 
increase the likelihood or magnitude of any effect of the FUS with MB procedure on 
motivation.   
 
Figure 7. Random Dot Motion and Reward Magnitude Bias Task. Cues appear in the center of 




appear: A correct target appears on either the inside (towards the middle of the screen) or the 
outside (towards the edge of the screen) on the same side the intial cue, and a distractor target 
will appear opposing the correct target as well as moving dots will appear where the initial cue 
was. Horizontal and vertical bars indicate high and low reward respectively. Reward 
magnitude is random so subjects cannot predict reward order. 
Once the NHP touched the initial cue, the display was updated to show a 
random dot motion stimulus and two secondary targets of the same shape, color and 
intensity as the cue. The dots appeared in a circular aperture. A percentage (0-70%, step 
size of 10%) of the dots moved coherently toward one target while the remaining dots 
moved randomly [123]. If the NHP touched the target towards which the dots were 
moving, the response was scored as correct and the NHPs. received the amount of 
water reward corresponding to the orientation of the targets. If the NHP touched the 
other target (the ‚distracter‛), the response was scored as incorrect and no reward was 
given. If the NHP touched any other part of the display or failed to touch the display 
altogether, the trial was scored as a failure and was not rewarded.  
Each trial took a maximum of 4 seconds, and each stage of the trial had a time 
limit for the NHP to respond or the trial would reset. The initial cue was present on the 
screen for a maximum of 1.5 seconds, and the dots with the targets were on the screen 
for a maximum of 2.5 seconds. Trials that were ignored or aborted would be recycled 
and presented again.  Reaction time (RT) to the initial cue was defined as the time from 
the visual onset of the cue until the first touch registered by the touch panel screen. 
Reaction time to the correct target or distracter was defined as the time from the onset 
of the moving dots until the subsequent touch registered by the to 
All NHP were full trained on the task (accuracy at discriminating dot direction > 
75%) prior to recording. NHP O was excluded from this portion of the study as they did 





All analysis pipelines were written and implemented in Matlab (Mathworks, 
MA, USA). The data were examined with two separate pipelines: The first examined the 
data sequentially over the duration of the experiment. The second divided the data into 
groups depending on the day of acquisition relative to the day of the FUS with MB 
procedure (-1, 0, 2, 3, 4 and 5+ days).  
For the first pipeline the mean raw reaction time (RT) were sorted by day, and 
response (to either the initial cue or correct target). A one-way ANOVA was used to 
detect significant variance within each NHP across the duration of the experiment. 
Touch error (TE) to the cue and target were also analyzed using this pipeline. TE was 
defined as the distance between where the NHP touches the screen and the center of the 
cue or target stimulus  
For the second method, days -1 and 5+ were considered to be a baseline since 
previous work has shown that the BBB openings created with the pressures being 
applied with this study close within three days [14]. This gives an additional two-day 
buffer to ensure the BBB has completely closed. A one-way ANOVA with Tukey’s HSD 
criterion (p < 0.05) was used for analysis of the RT and TE between groups to the initial 
cue and correct target. These groups were further divided according to which hand was 
used to respond and reward level. The average difference and confidence interval 
between low and high reward as well as ipsilateral and contralateral hand for RT and 
TE was found for each day. Days were determined to have significantly different means 
to day 0 if the 95% confidence interval of the mean did not overlap with the 95% 
confidence interval of day 0.  
Random dot motion accuracy was divided into groups using the same conditions 




correct trials) from each group was sorted by coherence level and fit with a 
psychometric curve (Naka-Rushton). Psychophysical threshold for detecting direction 
of motion was determined as the coherence level corresponding to 80% correct 
responses.   
3.4 Results 
Vital Signs 
Throughout the duration of the FUS procedure, the NHP vital signs were 
monitored and recorded. There were no significant differences between the recorded 
values for all the NHP in this study and previously published data for average vitals of 
macaques under isoflurane for heart rate and mean arterial pressure (student t-test, p < 
0.05) [128]. Figure 8 shows the average heart rate, blood O2 levels, respiration rate and 
blood pressure throughout the FUS procedure. There was no significant difference 
between vital recordings with the same NHP when either the targeting region or the 
acoustic pressure changed (one-way ANOVA, p < 0.05). Once the NHP regained full 
consciousness (3 hours after the FUS with MB procedure), no qualitative differences in 
their behavior within the husbandry room was observed. NHP would return to normal 
locomotion, eating, drinking and in the case of N and O, normal social behavior 
(grooming, playing). The weight for all NHP stayed consistent across the study. The 
only decrease occurred on days after there was no behavioral testing due to a restriction 
of fruit rewards since testing did not occur. Food and water intake stayed consistent 
and the fluctuations were not significant when compared to a control NHP not being 





Figure 8. Vital Monitoring. Vitals collected at five points throughout the duration of the FUS 
with MB procedure.  Results in the grey shaded region indicate time-points acquired during the 
FUS proceure. 
MRI Analysis 
The BBB opening was verified in 98% of the FUS procedures by comparing each 
NHP T1-post with the respective T1-Gado. Table 2 shows the number of times opening 
was achieved per location in each NHP. A typical representation of size and location of 
openings for the NHP is presented in Figure 9. Average volume of opening was 203 
mm3 with an average focal shift of 3 mm between the center of BBB opening and the 
planned target region. Table 3 lists the sizes of openings per NHP for each targeted 
area. No damage (hemorrhage or edema) was observed in the T2-weighted and SWI 




MB (n = 57). There were four cases where the T2-weighted scans exhibited hyperintense 
voxels in the area of targeting indicating possible edema. These occurred with NHP N 
and A only. These cases appeared on the final FUS procedure for N and the final three 
procedures for A. Figure 10 shows T2-weighted scans from two of the four cases with 
hyperintense voxels in the target area as well as T2-weighted scans one week later 
showing no hyperintense voxels in the target area. No hyper- or hypointense voxels 
were detected in the target region on the SWI scans for all NHP.  
 
Figure 9. Contrast Enhanced Blood-Brain Barrier Opening. The blue region shows a 10% 
increase in contrast over the background. A) Opening in the putamen of A. B) Opening in the 





Figure 10. T2-weighted MRI and SWI scans of NHP N and A. T2-weighted sequences can be 
used to detect potential edema. The first column shows no atypical hyperintense voxels in the 
target region. The second column shows atypical hyperintense voxels in the target region. The 
third column verifies the atypical hyperintense voxels from the previous week were no longer 
present. The fourth column shows the SWI scans from the day when hyperintense voxels were 
detected on the T2 scan (acquired the same day as column 2). 
Table 2. Targets and BBB openings of FUS with MB procedures for each NHP and 
duration of RDM + RMB task. 
NHP Target # of FUS BBB opening Duration of Task 
A L. Putamen 12 12 13 mo 
N R. Putamen 9 8 15 mo 
Ob L. Putamen 4 4 4 mo 
Table shows the times the FUS targeted each location, the success of each procedure and the 







Table 3. Volume of BBB opening per NHP and location. 
NHP Brain Target Acoustic Pressures (kPa) and Volume of Opening (mm3) 
A L. Putamen 300: 494 ±185 
N L. Putamen 200: 704, 275: 118 ±18 
N R. Putamen 400:  29 ±23 
N L. Caudate 250: 177 ± 182 , 300: 326  
O L. Putamen 250: 1792± 1447, 275: 2480±1550 
O L. Caudate 200: 459 ± 61 , 250:1438 ± 823 , 275: 220  
Ob L. Putamen 400: 418 ± 347 
Table shows the BBB opening volume per target location, animal and pressure. 
Behavioral Task 
Three NHP (A, N, Ob) were tested on the RDM + RMB task outlined in the 
methods section that recorded RT, TE, motivation and decision-making. Throughout 
the 4-15 month duration of the experiment, the FUS procedures were conducted 
targeting the putamen as shown in Table 2. RT for the initial reach to the cue is a simple 
reaction time. RT for the second reach to the target is a choice reaction time, as the NHP 
must choose between the correct and incorrect targets. 
The within session average raw RT and TE for each animal was examined across 
the duration of the experiment and shown in Figure 11. Only NHP A showed a large 
fluctuation (> 200 ms) in RT across sessions. These fluctuations were not associated with 
the FUS with MB procedures. NHP N did show an increase in RT to the cue during 
days 150-178 but returned to baseline. Similarly, there was a trend of increased RT to 
the target for NHP N starting on day 77 in which the RT remained elevated for the 
remainder of the experiment. Average raw TE was more consistent for each NHP, 




to the correct target over the first 30 days then remained at the lower TE value the 
remainder of the experiment.  
 
Figure 11. Raw Reaction Time and Touch Error to Initial Cue (left column), and to the Correct 
Target (right column). Blue diamonds indicate raw reaction time in seconds to either the initial 
cue or correct target. Red asterisks indicate raw touch error to either the initial cue or correct 
target. Reaction time is plotted on the left vertical axis while touch error is plotted on the right 




Figure 12 shows data grouped by day relative to the day of sonication. Average 
RT to the cue and target increased significantly (one-way ANOVA with Tukey’s HSD 
criterion p < 0.05) for all NHP on the day of the FUS with MB procedure compared with 
other days. Figure 12 shows that for NHP N and Ob there was a decrease in RT on days 
2 and 3 after the FUS with MB procedure compared to the other days. A similar 
decrease was only observed on day 4 for NHP A. Within five days RT had returned to 
baseline for all NHP. 
 
Figure 12. Average Reaction Time to Initial Cue (left column), and to the Correct Target (right 




For all NHP there is a significant increase in reaction time on day 0 compared to the rest of the 
days (p < 0.05). The numbers above each average indicate the n value for that group. The 
horizontal bar indicates baseline reaction time. 
Touch error (TE) was assessed as the distance from where the NHP touched the 
screen to the center of the cue or target stimuli. Reaching errors are shown in Figure 13. 
The average TE to the cue increased significantly for NHP Ob and N but decreased for 
NHP A on the day of the FUS with MB procedure compared to the other days (one-way 
ANOVA with Tukey’s HSD criterion p < 0.05). As shown in Figure 13, the TE to the 
correct target had less variance than the TE to the cue for all NHP. There was no 
significant change in TE to the correct target on day 0 compared with the rest of the 
days for NHP Ob. NHP N and A showed multiple days with significantly different TE 
to the correct target from that of day 0.  
Each FUS procedure was performed on only one hemisphere at a time. It might 
be expected that sonication would have stronger effects on reaches made with the hand 
contralateral to the sonicated hemisphere. This result was quantified by separating 
responses made with the hand contralateral or ipsilateral to the treated hemisphere. The 
ipsi-contra difference was used because overall RT and TE can vary from day to day. 
Figure 14 shows the average ipsi-contra RT difference for each day. When initially 
reaching for the cue, all NHP showed a significant hand bias on most non-sonicated 
days (student t-test, p < 0.05), but the bias was not consistent across animals; Ob was 
faster with the contra hand, N was faster with the ipsi hand and A showed different 
biases on different days. The biases for all NHP were smaller and less likely to be 
significant when reaching for the target. On sonication days (day 0), none of the NHP 






Figure 13: Average touch error to initial cue (left column), and to the correct target (right 
column). Blue indicates group average while red is the 95% confidence interval for the mean. 
There was a significant difference touch error to the cue on day 0 and the majority of the rest of 
the days (p < 0.05). There was a significant difference touch error to the correct on day 0 and 
some of the other days (p < 0.05). The numbers above each average indicate the n value for that 





Figure 14. Difference in Average Reaction Time between the Ipsilateral and Contralateral 
Hands as a Function of day Relative to the Day of the FUS Procedure. Responses to the cue 
are plotted in the left column. Responses to the target are plotted in the right column. Blue 
indicates group average (average ipsilateral hand reaction time – average contralateral hand 
reaction time) while red is the standard error of the mean. The numbers indicate the n value for 
that group. Asterisks above each average indicate a significant difference between the 




 Figure 15 shows hand bias for touch error as the difference in average TE 
between ipsilateral and contralateral. Similar to the RT results, all NHP show significant 
hand biases (student t-test, p < 0.05) when reaching to the cue on non-sonicated days, 
but no significant differences on the day of sonication. When reaching for the target, no 
NHP showed a significant hand bias on the day of sonication. Only NHP A showed 
significant differences on non-sonicated days. Considering the RT and accuracy data 
together, sonication tended to reduce the significance of the animal’s pre-existing hand 
bias. However, because these biases were idiosyncratic, sonication did not 
systematically make reaches with the contralateral hand slower or less accurate.  
Differences in RTs to high and low reward stimuli can be an index of motivation. 
Figure 16 shows the difference in RT between the low and high reward to the initial cue 
and correct target. On non-sonicated days, NHP Ob and N were faster in reaching for 
the initial cue and slower in reaching for the target when the reward was high. NHP A 
showed the opposite pattern. On sonicated days, reward magnitude had no effect on 






Figure 15. Difference in Average Touch Error Between Ipsilateral and Contralateral Hands as 
a Function of Day Relative to the Day of the FUS Procedure. Responses to the cue are plotted 
in the left column. Responses to the target are plotted in the right column. Blue indicates group 
average (average ipsilateral hand touch error – average contralateral hand touch error) while 
red is the standard error of the mean. The numbers indicate the n value for that group. Asterisks 
above each average indicate a significant difference between the differences in reaction time on 




   
 
Figure 16. Difference in Average Reaction Time Between Low and High Reward as a 
Function of Day Relative to the Day of the FUS. Responses to the cue are plotted in the left 
column. Responses to the target are plotted in the right column. Blue indicates group average 
(average low reward reaction time – average high reward reaction time) while red is the 
standard error of the mean. The numbers indicate the n value for that group. Asterisks above 
each average indicate a significant difference between the differences in reaction time on day 0 




The difference between the low and high reward on TE was also investigated. 
Figure 17 shows the average difference in TE between the low and high reward for both 
the initial cue and the correct target. On non-sonicated days, NHP Ob and N tended to 
be less accurate in reaching for the cue on low-reward trials (as well as being slower, as 
shown in Fig 16). When reaching for the target, Ob and N rarely showed any accuracy 
difference between low and high reward trials. NHP A showed mixed results when 
reaching for either the cue or target. On sonicated days, none of the NHP showed any 
difference in accuracy between high and low reward trials. 
Considering the RT and accuracy data together, all NHP showed significant 
differences between high and low rewards on non-sonication days. These differences 
could be attributed to the motivational significance of reward size, especially NHP Ob 
and N’s tendency to be faster and more accurate on high reward trials when reaching 
for the cue. The lack of any significant difference in RT or accuracy on sonicated days 
suggest that sonication may have slightly dampened the NHP’s motivation to reach 





Figure 17. Difference in Average Touch Error Between Low and High Reward as a Function 
of Day Relative to the Day of the FUS Procedure. Responses to the cue are plotted in the left 
column. Responses to the target are plotted in the right column. Blue indicates group average 
(average low reward touch error – average high reward touch error) while red is the standard 
error of the mean. The numbers indicate the n value for that group. Asterisks above each 
average indicate a significant difference between the differences in reaction time on day 0 




The previous results raise the question of whether sonication affects the NHP’s 
cognitive abilities. Decision-making can be assessed by performance accuracy, i.e. 
frequency of selecting the correct target. Overall, each animal exhibited > 76% accuracy 
in selecting the target indicated by the dot direction which was significantly over 
chance. This accuracy did not significantly change on days when the FUS with MB 
procedure occurred (student t-test, p > 0.05).  
A more sensitive measure of decision-making is the coherence threshold for 
identifying direction of motion. Coherence threshold is the percentage of coherently 
moving dots for which the subject correctly judged motion direction on 80% of the 
trials. The average coherence thresholds for all NHP were at or below 31%. Figure 18 
plots percent correct direction discrimination as a function of motion coherence for 
NHP N. The solid curves are the Naka-Rushton curve fits to the raw data. Results for 
NHP Ob and A were similar. NHP N exhibited the lowest average coherence thresholds 
across groups for both right and leftward moving dots at 15% and 17% respectively. 
Coherence thresholds for each group are shown in Table 4. Thresholds were not 
significantly elevated on the day of sonication (day 0), if anything, they were lower, 
indicating that sonication did not impair (and may have improved) the NHPs motion 





Figure 18. Naka-Rushton Model Fits of Accuracy Against Coherence for the RDM Task 
Completed by NHP N. The red and blue circles indicate the average percent correct for each 
coherence level for the right and leftward moving dots respectively. The numbers in the top left 
corners correspond to days relative to the FUS with MB procedure. Other NHP coherence plots 
follow similar trends of no large variation in response to the FUS with MB procedure. 
Table 4. Dot coherence percentages for 80% accuracy. 
Day -1 0 2 3 4 5 
A Right 19% 13% N/A 24% 15% 22% 
A Left 14% 22% N/A 33% 23% 26% 
N Right 13% 14% 17% 15% 15% 15% 
N Left 16% 15% 19% 15% 17% 17% 
Ob Right 22% 30% 66% N/A 31% 41% 
Ob Left 24% 19% 34% 30% 27% 34% 
Table 4 is divided into days relative to the FUS with MB procedure, animal and the direction of 





Figure 19: Raw Reaction Time Data for Alert Behavioral Testing for NHP A. Reaction times 
for individual trials as a function of time during the experiment. A linear regression was 
performed on all the data sets and is shown as the black line. The slope of the black line is 
positive for the No Anesthesia group, while the slope of the line is negative for the Anesthesia + 
FUS and Anesthesia Only groups. 
Individual responses to the RMB + RDM task are shown in Figure 19. The data 
sets in the No Anesthesia and the Anesthesia + FUS columns are plotted in figures 11, 
12, 14, and 16. A linear regression was performed on all the data sets and plotted as the 
black line in Figure 19. The slope of the No Anesthesia linear fit is positive while the 
slope of the Anesthesia + FUS linear fit is negative. Typically, as the NHP complete the 
task they become satiated and are less motivated to respond as quickly to the stimuli, 
and thus have an increase in reaction time over the duration of the experiment. This 
was observed in the No Anesthesia group, but the opposite was observed for the 
Anesthesia + FUS group. The negative slope for a linear fit is also observed with the 
Anesthesia Only group. This suggests that there were lingering effects of the anesthesia 




performed after the study had been completed, and thus the effects of the lingering 
anesthesia were not removed from the prior study figures. This linear regression 
analysis method was applied to all subsequent studies described in this thesis to ensure 
that the observed effects were not affected by the anesthesia or the FUS procedure. 
The behavioral data recorded on the days when the hyperintense voxels were observed 
on the T2-weighted MRI scans did not significantly vary from data acquired when there 
were no hyperintense voxels detected (student’s t-test, p < 0.05). Average RT and TE 
were not significantly different from the data acquired on other days when the FUS 
with MB procedure occurred. The difference in RT between the contralateral and 
ipsilateral hands also did not significantly vary from the other days when the procedure 
had occurred. 
3.5 Discussion 
A major hurdle for developing therapies prior to clinical trials is determining the 
safety of the procedure. Previous studies have shown that short-term applications of 
FUS with MB can safely open the BBB in multiple in vivo models such as mice and NHP. 
Here the safety for long-term applications of FUS with MB BBB opening in NHP was 
verified through vital sign monitoring, MRI analysis and behavioral testing. The 
combined results show that FUS-mediated BBB opening in the basal ganglia does not 
have long-term effects on the general physiology of the NHP, the structure of the 
targeted brain regions nor on decision and motor function. 
Safety 
As this technique moves closer to clinical testing, the safety of the procedure 
must be thoroughly investigated. During surgical procedures, heart rate, respiration 




NHP has been at a deep steady state of anesthesia for prolonged periods [129]. The vital 
signs monitored during the FUS with MB procedure did not exhibit any significant 
variations outside of normal cardiovascular or pulmonary function. Figure 8 shows 
inter-NHP but no intra-NHP variations in heart rate, blood pressure, respiratory rate, 
CO2 emissions and SPO2 levels. An initial drop of the heart rate occurred after induction 
of anesthesia and can be attributed to the effects of isoflurane (Figure 8).  
 Agreeing with previous long-term studies on mice, gross physiological changes 
in weight, food and water consumption, activity levels, mobility or emotional state with 
the NHP over the course of repeated FUS with MB procedures were not observed [20]. 
The contrast enhanced T1-weighted MRI scans obtained at least 5 days after the FUS 
with MB procedure at the middle and end of the experiment did not indicate increased 
permeability in the targeted regions. These scans show that repeated BBB opening via 
the FUS with MB applications does not permanently increase the permeability of the 
targeted area.  
T2-weighted MRI and SWI sequences were used to determine possible damage at 
the BBB opening region. Previous work suggests that the MB size and acoustic pressure 
are the critical parameters in dictating both the opening size and safety [14, 130]. Only 
NHP N and A exhibited hyperintense spots in the T2-weighted MRI sequences for one 
and three applications of FUS with MB, respectively. The hyperintense spots on the T2-
weighted scans suggest possible, blood, or edema [92]. There was no hypointense signal 
in the same area for the SWI scans, which eliminates the possibility of hemorrhage 
[131]. To rule out permanent lesions T2-weighted and SWI sequences were acquired a 
week after the initial detection and revealed no hyperintense or hypointense voxels in 
the region where they were previously observed (Figure 10). Thus, the hyperintense 
spots could have been caused by edema which was cleared over the course of a week. 




NHP N with 4-5µm MB. Previous pressures of 440-700 kPa with Definity MB were 
shown to cause hypointense spots in T2*-weighted imaging as well as hemorrhaging in 
the thalamus region after histological investigation [16]. In the current study, the NHP 
were not euthanized as they were already selected to be used in future experiments and 
therefore histology was not available. This was a limitation to the scope of this study as 
the histology might have revealed blood cell extravasation, neuronal death or an 
immune response in the areas of repeated BBB opening. From previous studies where 
histology was conducted after short-term application of the FUS with MB procedure on 
NHP, one could expect some petechiae and possible damaged capillaries [16]. No 
significant variations in RT or TE on days when the hyperintense voxels were detected 
compared to the days without any hyperintense voxels. Thus, the presence of possible 
edema did not have an effect on the behavioral results for that given day. Over the 
course of all FUS with MB procedures, there was no change in the NHP ability to 
perform daily functions or a change in their disposition. With the parameters and 
targets selected within this study, it was demonstrated that repeated FUS with MB 
procedures could be safely applied long-term.  
As mentioned previously the parameters utilized for the FUS with MB 
procedures within this study were originally derived from previous studies in the 
Konofagou lab [12, 15]. Although the NHP are within the same relative size/age group, 
each NHP has FUS parameters that are optimal for them. NHP A and O were smaller 
subjects (5-6kg) and substantial BBB opening could be achieved with lower pressures 
(300 kPa), while NHP N and Ob (8-9kg) were physically larger and required higher 
pressures (400 kPa) to achieve similar opening sizes. These selected pressures also 
allowed for safe BBB opening with the majority of the experiments conducted in this 
study. This supports the notion that while there are general guidelines for parameters 




identified for individual subjects. This will be important in the future when the FUS 
with MB procedure makes the step into the clinic with patients. 
Behavioral task 
The regions of the basal ganglia targeted in these experiments are involved in 
decision-making and motor control. Gold and colleagues have shown that neurons in 
the caudate nucleus of NHP signal decision variables during a random-dot motion task 
similar to the one used in this study [132]. Hikosaka and colleagues have documented 
the involvement of the caudate in reward-based reaction-time differences [109, 120]. 
Pilot experiments in our lab undertaken in preparation for the current study also 
provided evidence that targeting the basal ganglia with FUS technique can have 
profound behavioral effects. In one NHP (M, adult male rhesus), unilateral delivery of 
FUS with MB to the caudate resulted in hemispatial neglect contralateral to the treated 
hemisphere that lasted for roughly 24 hours. This was likely due to excessive FUS 
pressure. For the results reported from the experiments in this study, no NHP 
responded to the FUS procedures with physical deficits as discussed above.  
The RDM + RMB task was well suited for determining if there were any effects of 
the FUS with MB procedure on either the motor signal pathway or the decision making 
pathways associated with the basal ganglia [26, 106]. Movement commands initiated in 
the motor cortex are processed through the basal ganglia and the cerebellum before 
being sent to the spinal cord [106]. The dorsal parts of the caudate and putamen are 
associated with sensorimotor function while the ventral parts are associated with limbic 
functions [107]. Thus, if the FUS with MB procedure disrupted the pathways in the 
basal ganglia regions, motor and decision making deficits should be observable [107]. It 
is of interest that there was a significant increase in the RT to both the initial cue and the 




within five days. Similarly, the average TE to the initial cue was elevated for NHP N 
and Ob and decreased for NHP A, which also returned to baseline within 5 days. 
Behavioral testing that occurred on the same day as the FUS procedure was done 
several hours after the procedure, and therefore after a period of about an hour of 
anesthesia. However, it was unlikely that the isoflurane had an effect on behavioral 
responses. It has previously been shown that isoflurane has the fastest recovery time of 
anesthetic drugs for NHP with a recovery time of 20 minutes even for high doses (3-4%) 
[129]. Lower doses of isoflurane (2% max when placing the NHP into the stereotax) 
were applied, and the dosage was decreased to 0.5% during the final five minutes of the 
procedure minimizing their total exposure to anesthesia. 
Examining the RT difference between hands was a useful indicator if the FUS 
with MB procedure had disrupted the motor processing pathways in the basal ganglia 
as only one hemisphere was targeted during each procedure. Similar to humans, NHP 
have a preferred hand for most tasks, and thus have faster RT for that hand [134, 135]. 
This hand preference can be seen on the baseline days (-1, 5+) for the RT to the cue for 
all NHP in Figure 14. If the FUS procedure had affected the basal ganglia only in the 
targeted hemisphere, the effects should have been observed in the contralateral hand, 
thus changing the difference in RT between the two hands. As the average difference 
RT between the ipsilateral and contralateral hand to the initial cue for NHP N and A 
was below 0 indicating his ipsilateral hand was dominant for both the baseline days 
and days where the FUS procedure occurred. Similarly, average difference in RT 
between hands for NHP Ob was above 0, indicating his contralateral hand was 
dominant. Interestingly this dominance switches when responding to the correct target 
for both NHP Ob and N. This inversion in dominance to the correct cue and correct 
target was not observed in NHP A. Regardless, hand dominance was not affected by the 




procedures have an effect on handedness nor specifically on the RT of the contralateral 
hand for two of the three NHP.  
As expected with the RMB portion of the task, most of the NHP responded with 
faster RT to the high reward cue, than the low reward cue for most of the days as the 
average difference between the low and high reward was above 0  (RT to cue seen in 
Figure 16). These results agree with previous studies where NHP made saccadic eye 
movements to complete an RMB task [120]. In that study, NHP had faster saccades to 
the high reward, while slower saccades to the low reward. The bias in responding faster 
to the high reward was reversed for RT to the correct target as the average difference in 
RT between the low and high reward was below 0 indicating a faster response to the 
low reward. This could be attributed to a speed accuracy tradeoff, as the higher reward 
was more salient and thus the NHP took additional time to select the correct target 
[136]. The responses from NHP A were more varied across days and did not show the 
bias that was observed in both NHP N and Ob. The bias seen with NHP N and Ob was 
not affected by the FUS with MB procedures. Overall, the FUS with MB procedures did 
not have an effect on the reward bias for the two NHP that followed the paradigm 
originally.  
Touch error was an important factor for determining if the FUS with MB 
procedure had an effect on the basal ganglia. If the average distance between the target 
and the point where the NHP touched the screen increased or became more erratic 
between separate days to the point of significant variation, it could indicate that the FUS 
BBB opening procedure had an effect on the voluntary motor control pathway [107]. As 
with Parkinson’s, the disruption of the motor pathway can lead to undershooting when 
reaching for a target [137]. As seen in Figure 13 most NHP showed a significant 
difference between day 0 and the other days for the initial cue. There were fewer days 




days. This could have been caused from the prior position of the NHP hand before 
selecting the correct target, as it would be in the relative same position for each trial 
having just selected the initial cue. There would be more variation in TE to the initial 
cue as the NHP could have its hand resting in various positions before reaching to the 
initial cue, increasing the variability of the TE. NHP N did not exhibit any significant 
variation of the TE to the target between day 0 and the other days over the duration of 
the behavioral recordings independent of hand or reward magnitude. NHP Ob only 
showed two days where there was a significant difference in TE to the correct target 
between day 0 and the rest of the days with respect to reward magnitude, but similar to 
NHP N did not show any significant variation with respect to the difference between 
hands. This indicates the FUS with MB procedure did not have an effect on touch error 
to the target.   
The RDM component of the task tested whether the FUS with MB procedure was 
having an effect on the decision-making pathways associated with the basal ganglia 
[138, 139]. The coherence threshold in Figure 18 does not vary more than 4% across each 
group. The variance of the detection threshold between days and the individual daily 
threshold for detection was low and consistent with previous investigations using the 
RDM task for the majority of the days [140, 141]. NHP Ob exhibited the largest variation 
between baseline coherence threshold and the day of the FUS with MB procedure with 
a 10% variation, while NHP A and N exhibited less than 8% variation. This percentage 
was comparable to variation between non-FUS with MB procedure days and does not 
indicate the FUS with MB procedure had an effect on the decision-making pathways in 







As FUS mediated BBB opening moves closer towards clinical feasibility, the 
safety of repeated FUS BBB opening procedures must be characterized in the NHP 
model. Here the results demonstrate that repeated BBB opening at the caudate and 
putamen regions in NHP can be achieved safely without hemorrhage or permanent 
edema, and to not cause a permanent effect on RT and decision making responses with 
the applied FUS parameters. The findings support that FUS is a promising technique for 
clinical applications as it is the only non-invasive procedure that can be used to 
chronically and accurately open the BBB safely in both cortical and subcortical regions 
of the brain without causing damage to the structure or neurological pathways within 
it. 
3.7 Contributions 
 In this chapter, the safety and efficacy of chronic FUS BBB openings in the basal 
ganglia of NHP was investigated. While there was one prior study that repeatedly 
applied this technique to NHP, their study was short-term and lasting a maximum of 
six weeks. For the first time the results demonstrate that the FUS technique can be 
applied to the same brain structure over a period of 4-20 months without any long-term 
side effects. This is critical as the technique progresses towards clinical testing in 
humans. As current drug therapies treating neurological diseases such as PD require 
repeated drug administration, this technique may need to be applied for long periods, 
facilitating the delivery of therapeutic drugs. Results from this study determining the 
behavioral effects was also important to explore before starting the FUS mediated drug 
delivery in specific aim 2. It was shown on the day of the FUS procedure, there was an 
effect on behavior, but this effect was not long lasting and behavioral results returned to 




pipeline, along with the base pipeline for behavioral testing which was utilized in the 
following chapters. The results discussed here have all been published in peer reviewed 
scientific journal [19].  
 Regarding the research contributions, Tobias Teichert, PhD (Neuroscience, 
Columbia University) and Fabrice Marquet PhD (Biomedical Engineering, Columbia 
University) originally mentored and assisted with the initial FUS experiment. Shih-Ying 
Wu MS (Biomedical Engineering, Columbia University) assisted with the initial FUS 
experiments. Carlos Sierra Sanchez, PhD (Biomedical Engineering, Columbia 
University) and Marilena Karakatsani, MS (Biomedical Engineering, Columbia 
University), assisted with the FUS experiments and the microbubble fabrication for 
experiments. Amanda Buch, BS (Biomedical Engineering, Columbia University) assisted 
with the FUS experiments, the microbubble fabrication for experiments and with the 
behavioral testing. Shangshang Chen, BS (Computer Science, Columbia University) 












Specific Aim 2 
Drug Delivery to the Basal Ganglia via Focused Ultrasound with 
Microbubbles Blood-Brain Barrier Opening in Non-Human 
Primates and Mice 
Prior studies verified the delivery of various neuroactive molecules to the brain 
parenchyma via FUS to treat brain tumors or promote neurogenesis, yet none of those 
investigations delivered molecules causing a pharmacodynamical effect on the response 
of the subjects to behavioral testing. The second aim of this thesis addresses this issue 
and explores the potential of using the FUS technique to deliver large molecules, as well 
as low doses of D2-antagonists, to the basal ganglia in mice and NHP to elicit 
pharmacodynamical modulation of their behavior. The study here builds on the 
findings in chapter 3 and takes into account the effects of the FUS technique on the 
behavioral testing on day 0. Thus, the effects of successful drug delivery can be 
determined without the confounding effects of the FUS technique.  
4.1 Abstract 
The native blood-blood brain barrier (BBB) promotes brain homeostasis, but also 
greatly impedes the treatment of neurological disorders such as Parkinson’s or 
Alzheimer’s disease by preventing 99% of currently available drugs from crossing into 
the brain parenchyma. Focused-ultrasound with intravenously administered 
microbubbles (FUS) has been shown as a technique to non-invasively open the BBB in 
specific brain regions. Here the FUS technique was used to open the BBB in 
anesthetized non-human primates (500 kHz, 200-400 kPa, 4-5µm MB, 2-minute 




sonication) to deliver a low dose of D2-antagonists (haloperidol or domperidone) to 
the basal ganglia. After administration of the D2-antagonist, behavioral testing was 
conducted with each species. The open field and rotarod test were employed to test the 
motor effects of low dose haloperidol on mice after opening the BBB in the striatum. 
There was a significant decrease in motor activity of mice during the open field test for 
the group when low dose haloperidol had been administered after the BBB was 
opened. The NHP performed a random dot motion with reward magnitude bias 
behavioral task to quantify the effect of the low dose haloperidol on their cognitive, 
motivational and motor function. Behavioral results show successful delivery of 
haloperidol after the BBB was opened with a significant increase in the reaction time to 
the target stimuli. There was also a significant increase in touch error to the initial cue 
with the hand contralateral to the application of the FUS technique for all NHP. There 
was no significant effect on the threshold level of dot motion coherence, but there was 
an increase in overall accuracy to the task for 2/3 NHP. After administration of 
domperidone following BBB opening targeting the caudate, two of the NHP exhibited 
hemilateral neglect on the side of their body contralateral to the FUS application. 
Overall, the results show that the FUS technique can be effecting in facilitating delivery 
of low dose drugs for pharmacodynamical behavior modulation. 
4.2 Introduction and Study Design 
As mentioned previously, the blood-brain barrier (BBB) is ubiquitous in all 
vertebrate physiological systems and regulates the flux of molecules into the brain 
parenchyma [35]. The protective benefits of the BBB is also a major hindrance when 
attempting to treat neurological diseases or disorders as it blocks 99% of all small 
molecule, and almost all large molecule drugs from crossing into the brain [4]. The tight 
junctions between the endothelial cells act as a physical and metabolic barrier excluding 




techniques to circumvent the BBB for drug delivery either provide target specificity 
through invasive procedures, or have nonspecific delivery and are non-invasive [81, 82, 
83]. Focused ultrasound coupled with microbubbles (FUS) has been proven to non-
invasively open target specific locations in the BBB with multiple in vivo models [9, 10, 
11, 12]. This technique also allows the BBB to close within hours to days, providing a 
complete non-invasive procedure to circumvent the BBB [14].  
The development of the FUS technique as a non-invasive method to facilitate 
drug delivery has two specific applications; the first to facilitate the treatment of 
neurological diseases and disorders in the clinic, the second as a simple technique 
allowing non-invasive drug delivery for neuromodulation during behavioral 
experiments within the laboratory. Multiple groups have utilized the FUS technique to 
delivery various neuroactive drugs across the BBB [21, 22, 23, 93, 94, 95, 96, 97, 98, 99, 
100, 101, 102, 103, 104]. These experiments usually involve the treatment of preexisting 
neurodegenerative disorders, or deliver agents to provide neuroprotection or 
neuroregeneration. Doxorubicin, a drug utilized in cancer chemotherapy, has been 
successfully delivered to the rat brain for treatment of tumors after applying the FUS 
technique to the diseased region of the brain [22]. Neuoprotective and growth factors 
such as neurturin and GDNF have also been delivered in mice brains after the FUS 
procedure [21, 103]. The successes of the aforementioned studies were validated by the 
reduction of the targeted tumor, or the prevention of neurological tissue damage in 
Parkinson’s disease (PD) model mice. Recently, McDannold et. al. showed a dose 
dependent suppression of somatosensory evoked potentials when GABA was delivered 
to the somatosensory cortex in rats [105]. To date, FUS facilitated drug delivery for 
neuromodulation to external stimuli has not be investigated in NHP.  
Another challenging issue with treating neurological diseases using current drug 




common treatment for Parkinson’s disease involves daily doses of levodopa *147]. Since 
dopamine cannot cross the BBB, levodopa, which can cross the BBB, is administered 
orally and is converted into dopamine once it reaches the brain parenchyma [148]. 
Although this technique can be effective in the treatment of PD, levodopa is not brain 
region specific and increases the dopamine levels throughout the brain. Chronic 
applications of levodopa can also cause negative debilitating side effects such as 
dyskinesia [149]. The FUS technique could enhance current or pipeline drug therapies 
by allowing targeted delivery of the drug to brain regions intended for interaction with 
the drug. This would allow for a lower administered dose, reducing the overall chances 
for adverse side effects.  
In this study, the results demonstrate that the FUS technique is an effective tool 
for delivering low dose D2-antagonists to the basal ganglia region in both mice and 
NHP. Haloperidol and domperidone were selected as the D2-antagonists as 
domperidone does not readily cross the native BBB, while haloperidol can [150, 151]. A 
threshold dosage of haloperidol was determined as a dose that did not significantly 
affect behavioral testing after administration when the BBB was intact. This threshold 
dosage was used to explore if a low dose of a drug could achieve the same therapeutic 
effects when the BBB was opened at the target region as a full dose of the drug while 
the BBB was intact. The basal ganglia region was selected as it has been associated with 
voluntary motor control, motivation and decision-making [120, 121, 122]. After opening 
the BBB with the FUS technique and administering the D2-antagonist, each species 
completed behavioral tasks to determine the effect of the drug. The NHP performed 
either a random dot motion with reward magnitude bias task testing cognitive, 
motivational and motor function (haloperidol experiments), or were observed in an 
open field (domperidone experiments). Mice performed an open field and rotarod test 




well as verification of the BBB opening was conducted with both species. Behavioral 
results with both species indicate successful delivery of both haloperidol and 
domperidone to the basal ganglia.  
4.3 Materials and Methods  
Subjects and Ethics Statement 
The procedures with NHP described in this study were approved by the 
Institutional Animal Care and Use Committees (IACUC) of Columbia University and 
the New York State Psychiatric Institute (NYSPI). Two adult male Macaca mulatta 
(NHP: N, Ob) and one adult Macaca fascicularis (NHP: A) were used in all experiments 
(9-20 years old, 5.5-9.5 kg). Husbandry practices employed during these experiments 
were described in chapter 3.3.  
 For the mice experiments, all procedures were approved by the Columbia 
University IACUC and Columbia University’s Research and Compliance 
Administration System. Fifteen wild-type adult male mice (strain: C57BL/6, Harlan 
Sprague Dawley, IN, USA), weighing 20-25g were used for the mice experiments. There 
were three study groups of n = 5: Haloperidol/FUS+, Haloperidol/FUS- and 
Saline/FUS+. All mice were housed in husbandry rooms with a 12-hour light dark cycle 
with an average temperature of 22°C. The mice were provided standard rodent chow (3 
kcal/g; Harlan Laboratories, IN, USA) and bi-distilled water ad libitum.  
FUS Procedure 
The MB used in the both the mice and NHP procedures were fabricated in-lab a 




The FUS technique applied to all anesthetized NHP was previously described in 
chapter 2.3. The FUS technique was applied to NHP A 10 times, (n = 5 per behavioral 
group, Haloperidol/FUS+, Saline/FUS+) and the technique was applied a total of 8 times 
to NHP Ob and N (n = 4 per behavioral group, Haloperidol/FUS+, Saline/FUS+). 
The FUS technique for the mice was conducted with a single-element spherical-
segment 1.5 MHz FUS transducer. The center of the transducer was bored out allowing 
placement of a 10 MHz pulse-echo transducer for target alignment. The focal regions 
from both transducers were aligned. The FUS transducer was driven by a function 
generator (Agilent, CA, USA) with a 50-dB amplifier (E&I, NY, USA). A cone of 
degassed water was coupled with the transducer submersing the bottom membrane of 
the cone into a water bath above the head of the mouse. Anesthesia of the mice was 
maintained using 1.25-2% isoflurane mixed with oxygen. Mice were placed into 
stereotax positioning with incisor and ear bars. Targeting was achieved by positioning 
the transducer over the caudate/putamen region relative to the sagittal suture. The same 
MB used in the NHP experiments (chapter 3.3) were administered via tail vein injection 
as a bolus of 1ml/g with a concentration of 8 x 108/mL. An acoustic pressure of 300kPa 
with a PRF of 5 Hz at 100 cycles and a 60-second sonication duration were used for all 
mice FUS applications. 
Drugs 
Haloperidol, a D2 antagonist (R&D Systems, Inc., Minneapolis, MN), was 
selected as the drug for neuromodulation. Haloperidol powder was dissolved in saline 
and titrated to the concentration of 0.01mg/kg. D2 receptors in the putamen have been 
implicated with the indirect pathway between the striatum and the substantia nigra 
[152]. Before the task began, NHP were administered either saline or haloperidol 




maximum dose to not elicit a significant difference on the behavioral results compared 
to saline injections when the BBB was intact. On days when the FUS technique was 
applied, a five-hour wait period occurred before behavioral testing began allowing the 
NHP to fully recover from the anesthetics.  
Domperidone, another D2-Antagonist, was also selected for behavioral drug 
trials (Sigma Aldrich, MO, USA) [150]. Domperidone was initially dissolved in a low 
pH solution (0.5M lactic acid and saline) and titrated back to blood pH levels (between 
7.35-7.45). Domperidone was either administered five days after the most recent FUS 
application (to ensure BBB was closed) or three hours following FUS applications 
targeting the caudate.  
Behavioral Testing 
All NHP were fully trained for three months to respond via touch to visual 
stimuli presented on a 20-inch color LCD touch panel display (NEC 2010X with 3M SC4 
touch controller). The behavioral task was a random dot motion (RDM) decision-
making task with a reward magnitude bias (RMB) paradigm [120, 121, 122] The full 
description of the behavioral task employed can be found in chapter 3.3. As before, 
reaction time to the cue was defined as the onset of the cue stimulus appearing on the 
touchscreen monitor to the first contact recorded by the touchscreen. Reaction time to 
the target was defined as the onset of the target stimuli appearing on the touchscreen 
monitor until the first contact recorded by the touch panel. Touch error was defined as 
the distance between the point of first contact to the touchscreen monitor and the center 
of the stimuli.  
The pharmacodynamical effects of domperidone after opening the BBB at the 




the FUS technique the NHP were allowed to regain muscle posture (ability to sit up 
unassisted) and placed in a primate work chair. This allowed monitoring of the NHP 
and prevention of the NHP removing the IV catheter. Three hours after the application 
of the FUS procedure targeting the caudate region, domperidone was administered IV 
(2.5 mg/kg). Following injection NHP were allowed to move around the surgery suite 
while attached to a guidance pole. During this time qualitative observations from 
graduate student, professors as well as veterinary staff at NYSPI were recorded. 
Following this observation session NHP were returned to their husbandry rooms. 
All mice were tested with the open field and rotarod behavioral test on day -1 
(one day prior to the FUS application). This was to establish a baseline for each 
individual animal. The open field test had a duration of ten minutes and recorded the 
total distance traveled, amount of rotations, and direction of rotations. The rotarod test 
lasted for a maximum of 200 seconds with a linearly increasing speed to 40 RPM. Mice 
were always tested with the open field before the rotarod test and given a ten-minute 
break between tests. 
MRI Analysis 
 All MRI scans (3T, Philips Medical Systems, MA, USA) for verification of safety 
and BBB opening in NHP were acquired 36 hours after the FUS procedure. Due to 
initial sedation for the FUS procedure, the NHP were not allowed to be anesthetized a 
second time in the same day, thus the MRIs were acquired on day 1. The MRI 
parameters used to acquire the images, as well as the image post processing were 
discussed in chapter 3.3.  
To validate the BBB opening in mice, the mice were anesthetized and placed into 




weighted 2D scans (TR: 230 ms, TE: 3.3 ms, NEX: 18, resolution: 86 µm x 86µm, 500 µm 
slice thickness, FOV: 22 mm x 16.5mm). These scans were acquired pre and post 
administration of contrast agent (gadodiamide). For safety verification T2-RARE 
sequences were acquired (TR: 330 ms TE: 10.9 ms, FOV: 22mm x 16.5mm, resolution: 86 
µm x 86µm, 500 µm). 
Data Analysis 
The data acquired for each NHP conducting the RDM + RMB task were divided 
into four groups determined by the drug administered (saline or haloperidol) and if the 
FUS technique had been applied on that day, or had not been applied for a minimum of 
5 days. The four main data groups were Haloperidol/FUS+, Haloperidol/FUS-, 
Saline/FUS+ and Saline/FUS- (the + and – here indicate days when the FUS procedure 
occurred and did not occur respectively). Prior studies had shown the BBB in NHP 
closes within three days of opening, thus selecting five days for the FUS- groups gave 
an additional two days to ensure the BBB was closed [15]. As discussed in chapter 3.4, 
the longitudinal safety study found applying the FUS technique to anesthetized NHP 
had an effect on their behavioral testing results on the same day (day 0) [19]. Thus, a 
linear regression was performed on the Saline/FUS+ data set and used to remove effects 
of the sonication from the Haloperidol/FUS+ data set. Linear regression was also 
performed on the Saline/FUS- to normalize the Haloperidol/FUS- group. This 
normalization was done with independently for the cue and target stimuli for both 
reaction time, and the touch error data. 
 Average reaction times (RT) were calculated for both normalized 
Haloperidol/FUS+ and Haloperidol/FUS- groups. Significance between groups was 
determined with the student t-test (p < 0.05). These main two data groups were then 




between the subgroups were done with student t-tests (p < 0.05). The difference in touch 
error between the Haloperidol/FUS+ and Haloperidol/FUS- groups for individual 
parameters (high, low reward; ipsilateral, contralateral hand) was found for each NHP. 
The change in RT and TE between those two main groups was determined to be 
significant if the 95% confidence interval for each mean did not overlap.  
 The accuracy in discerning the coherent direction of dot motion was divided 
similarly into the initial four main groups: Haloperidol/FUS+, Haloperidol/FUS-, 
Saline/FUS+ and Saline/FUS-. The performance accuracy for each hand with the main 
groups was sorted by coherence level and fit with a Naka-Rushton psychometric curve. 
The psychophysical threshold for detecting the direction of motion was determined as 
the coherence level corresponding to an 80% correct response to the task. These 
coherence thresholds were then compared across groups using student t-test (p < 0.05). 
Overall accuracy at selecting the correct target was determined for each group, and the 
significant difference in accuracy between groups was determined with a student t-test 
(p < 0.05). 
 Distance traveled, total rotations per direction and duration spent on the rotarod 
were analyzed from the mice behavioral experiments. Analysis was carried out with a 
1-way ANOVA (p < 0.05) to detect variation between the groups (Haloperidol/FUS+, 
Haloperidol/FUS-, Saline/FUS+). Student t-test (p < 0.05) was used to determine 









4.4.1 Low Dose Haloperidol in NHP 
MRI Analysis 
 Contrast enhanced T1-weighted MRI scans verified the BBB remained open 36 
hours (day 1) after the FUS procedure for 75% of the cases. NHP A and Ob still 
exhibited BBB opening at day 1 while NHP N only expressed a 42% detection of BBB 
opening on day 1. The red transparent overlays in Figure 20 show typical cases of 
detected BBB opening on day 1. For both NHP A and Ob the opening still covers most 
of the putamen, while NHP N only shows coverage along the edges. NHP A also had 
the largest volume of BBB opening on average (508 mm3) followed by NHP Ob (192 
mm3) and NHP N (87 mm3).  
 
Figure 20: Contrast Enhanced Blood Brain Barrier Opening for Drug Study. The red/yellow 
transparent color map indicates areas where BBB opening was detected 36 hours after 
application of the FUS technique. 
 The T2-weighted and susceptibility weighted image (SWI) scans for the majority 
of the FUS procedures did not show any abnormal hyper- or hypointense voxels in the 




There were three cases when NHP A exhibited abnormal hyperintense voxels in the 
target region on the T2-weighted scans during day 1. These hyperintense voxels were 
not present on day 7. The experiments with hyperintense voxels were not correlated 
with the haloperidol administered during behavioral testing on day 0 as two cases were 
after haloperidol administration and the third case was after saline administration. 
NHP N also exhibited one case with abnormal hyperintense voxels on the T2-weighted 
scan during day 1 that were not present on day 7 (Figure 22). For NHP N saline had 
been administered on day 0 for behavioral testing. For both NHP A and N, no hyper- or 
hypointense voxels were detected with the SWI scans. This suggests a transient edema 
without microhemorrhaging occurred, and was not present within seven days. The 
behavioral data recorded on the day prior to detection of the abnormal hyperintense 
voxels were not significantly different from the other data collected within the same 
group (Haloperidol/FUS+, and Saline/FUS+), thus the edema was determined to not 
have an effect on the behavioral results (1-way ANOVA, p > 0.05).  
 
Figure 21: T2-Weighted and SWI Scans for the Haloperidol Non-Human Primate Study. The 
scans here represent the majority of the FUS procedures, without hyper- or hypointense 





Figure 22: Case of Hyperintense Voxels for the Haloperidol Non-Human Primate 
Study. The Figure shows the T2-weighted and SWI scans for NHP N during the one case 
where hyperintense voxels were detected. The detection of the hyperintense voxels on 
the T2-weighted image suggests potential edema. No hyper- or hypointense voxels were 
detected in the region of interest on the SWI scan. Detection of hyperintense voxels on a 
T2-weighted scan only occurred once for NHP N and three times for NHP A.  
Behavioral Analysis 
All three NHP completed the random dot motion with reward magnitude bias 
behavioral task after IM administration of either a low dose of haloperidol (0.01mg/kg) 
or saline. Behavioral testing occurred either on the day of the FUS application (day 0), 
or at minimum five days after the FUS application to ensure the BBB was closed (day 
5+). Average reaction times to the cue and the target stimulus for both the normalized 
Haloperidol/FUS+ and Haloperidol/FUS- group for each NHP can be seen in Figure 23. 
Only NHP A exhibited a significant decrease in reaction time to the initial cue between 
the Haloperidol/FUS+ and Haloperidol/FUS- groups (student t-test, p < 0.001). NHP Ob 
and N did not show any significant difference in RT to the cue between those two 
groups. There was a significant increase in RT to the target stimuli between 
Haloperidol/FUS+ and Haloperidol/FUS- groups for both NHP N and Ob (student t-




showed a significant decrease between those groups to the target stimuli (student t-test, 
p < 0.001).   
 
Figure 23: Normalized Reaction Times to Cue and Target Stimuli Following Threshold 
Haloperidol Administration. Average normalized reaction time is plotted with the 95% 
confidence interval. Dots indicate significance as follows: • for p < 0.05, ••• for p < 0.001. 
 The main data groups of normalized Haloperidol/FUS+ and Haloperidol/FUS- 
data were divided into subgroups by reward value and response hand. Examining the 




revealed two interesting trends. Table 5 shows the p-values for comparing 
Haloperidol/FUS+ and Haloperidol/FUS- data within each subgroup per each NHP 
(student t-test). The results in Table 5 illustrates that NHP A had a consistent significant 
decrease in reaction time between the Haloperidol/FUS+ and Haloperidol/FUS- groups 
regardless of the subgroup (hand, reward level or stimuli; student t-test, p < 0.001). The 
other trend was both NHP N and Ob showed a significant increase in RT between the 
Haloperidol/FUS+ and Haloperidol/FUS- groups to the target stimuli for the majority of 
the parameters (student t-test, p < 0.001).  
Table 5: p-Values for Significance Between the Haloperidol/FUS+ and Haloperidol/FUS- 
normalized groups per parameter. 
 NHP A NHP N NHP Ob 
Cue-High p < 0.001 N/A N/A 
Cue-Low p < 0.001 N/A N/A 
Target-High p < 0.001 p < 0.001 N/A 
Target-Low p < 0.001 p < 0.001 p < 0.001 
Cue-Contra p < 0.001 p < 0.001 p < 0.001 
Cue-Ipsi p < 0.001 p < 0.001 p < 0.001 
Target-
Contra p < 0.001 p < 0.001 p < 0.001 
Target-Ipsi N/A N/A p < 0.01 
Green indicates a significant increase while yellow indicates a significant decrease. N/A 
indicates p > 0.05. 
 Since haloperidol could have an effect on the motor accuracy, and not just 
reaction time, touch error to the stimuli was also recorded during the behavioral testing. 
Touch error was defined as the distance between the first location the NHP contacted 
the touch monitor and the center of the displayed stimuli. The difference between the 
Haloperidol/FUS+ and Haloperidol/FUS- groups were found for each individual 
parameter in the subgroups (high or low reward, ipsilateral or contralateral hand 




compared to the other parameter within that subgroup (i.e. the difference in TE 
between Haloperidol/FUS+ and Haloperidol/FUS- groups for the high reward 
compared to the difference in TE between Haloperidol/FUS+ and Haloperidol/FUS- 
groups for the low reward). There was a significant increase in the difference of TE 
between the Haloperidol/FUS+ and Haloperidol/FUS- groups to the cue stimulus for the 
contralateral hand compared to the ipsilateral hand for all NHP (table 6, student t-test, 
p > 0.05). This significant increase was also observed between the high and low reward 
cue stimulus for NHP N only.  
Table 6: p-Values for Significance Between the Touch Error for Haloperidol/FUS+ and 
Haloperidol/FUS- normalized groups per parameter. 
 
NHP A NHP N NHP Ob 
Cue: High - Low N/A p > 0.05 N/A 
Target: High - Low N/A N/A N/A 
Cue: Contra - Ipsi p > 0.05 p > 0.05 p > 0.05 
Target: Contra- Ipsi N/A N/A N/A 
Yellow indicates a significant increase of the contralateral hand / high reward to the ipsilateral 
hand / low reward.  
 While RT and TE are useful for detecting changes with the motor activity of the 
NHP, they are not sufficient indicators of changes with the cognitive ability of the NHP. 
The decision-making performance of the NHP was determined by the accuracy of the 
NHP selecting the correct direction the dots were coherently moving in. Both NHP N 
and Ob showed an increase in overall accuracy in the Haloperidol/FUS+ over the 
Haloperidol/FUS- group, while NHP A showed a decrease in overall accuracy (Table 7). 
Each NHP exhibited at least 70% accuracy in selecting the correct target per each group. 
NHP A was also the only NHP to have a decrease in accuracy to the low reward for the 




larger increase in accuracy to the low reward compared to the high reward for both 
NHP N and Ob.  
Table 7: Overall Accuracy Percentage for Discriminating Dot Direction per Drug/Sonication 
Parameter 
 
NHP N NHP Ob NHP A 
Halo/FUS+ 83.43 77.80 76.39 
Saline/FUS+ 83.93 81.16 70.25 
Halo/FUS- 81.48 72.73 77.88 
Saline/FUS- 84.71 72.24 76.26 
Numbers displayed in the Table are in percentages. 
Table 8: Accuracy Percentage for Discriminating Dot Direction per Reward Level and 
Drug/Sonication Parameter  
 
NHP N NHP Ob NHP A 
 
High Low High Low High Low 
Halo/FUS+ 84.62 82.60 78.60 74.87 82.14 80.58 
Saline/FUS- 85.07 82.87 81.34 81.36 81.34 83.25 
Halo/FUS+ 83.72 79.56 77.99 69.75 81.01 82.13 
Saline/FUS- 85.28 84.47 77.16 70.21 81.43 80.68 
 Numbers displayed in the Table are in percentages. 
Determining the coherence threshold for detecting discrete motion is a sensitive 
parameter for quantifying decision-making performance. The coherence threshold is 
determined as the percentage of coherently moving dots to the correct target that can be 
discerned by the subject with an 80% success rate. The percent correct of dot direction 
discrimination as a function of motion coherence is shown in Figure 24 B for both NHP 
N and Ob. Both NHP responded more accurately accuracy for the FUS+ group 






Figure 24: Naka-Rushton Model fits of Accuracy to Coherence for the Random Dot Motion 
Task. A) The red and blue bars here indicate the responses to the accuracy of the FUS + and 
FUS- respectively. The whiskers indicate the 95% confidence interval. There was no significant 
difference across groups. B) The red and blue lines here indicate the Naka-Rushton fit to the 
accuracy per coherence level for the FUS + and FUS- data sets. The red and blue circles indicate 
the percent correct for each coherence level. The vertical and horizontal dashed lines indicate 
the coherence threshold for detecting the direction of the dots with an accuracy of 80%. 
4.4.2 Low Dose Haloperidol in Mice 
Blood-brain barrier opening was observed in all mice. Figure 25 shows a contrast 
enhanced T1-weighted MRI representative of the average BBB opening achieved in the 
caudate-putamen region of the mice. Hyperintense voxels were only detected in the T2 
RARE sequences for 3/15 of the procedures. Those mice were excluded from the 
behavioral analysis as prior studies have shown the presence of edema in the mice can 
induce behavioral deficits [153]. There was no significant difference observed between 
the groups for the duration the mice could remain on the rotarod without falling off (1-
way ANOVA, p > 0.05), with the majority of the mice remaining on the rotarod for the 
full 200 seconds. There was a significant decrease in the distance traveled in the 
Haloperidol/FUS+ compared to the Haloperidol/FUS- group (Figure 26, student t-test). 
This agrees with previously published reports of intracerebroventricular (ICV) injection 





Figure 25: MRI Blood-Brain Barrier Opening and Safety Validation for the Mice Study. 
Contrast enhanced regions for the T1-weighted scan indicate BBB opening. The T2-RARE image 
shows no abnormal hyperintense voxels, indicating lack of edema. Potential edema was only 
detected for 3/15 cases. 
 
Figure 26: Distance Traveled During an Open Field Test. The average and 95% confidence 
interval for both cases where low dose haloperidol had been administered IP with and without 
BBB opening. There was a significant decrease in the distance traveled between the two groups 





4.4.3 Domperidone in NHP 
MRI Analysis 
T2-weighted MRI scans acquired following the domperidone behavioral 
experiments indicated abnormal hyperintense voxels in the caudate region for NHP N, 
O and Ob. Abnormal hypointense voxels were also detected on T1-weighted scans in 
the caudate region of NHP N and O. No abnormal voxels were detected on T2-
weighted or SWI scans for NHP B. This initially suggests the presence of edema in NHP 
N, O and Ob (Figure 27). The hyperintense voxels were not detected on day 7 with T2-
weighted scans for any of the NHP. On day 7 there were hypointense voxels detected 
on the SWI scans for NHP N and O. This suggests the potential presence of a hematoma 
in the targeted region of the caudate for both NHP. The volume of area covered by the 
hypointense voxels did not decrease in size over the duration of two years and appears 





Figure 27: T2-Weighted and SWI Scans after Domperidone Administration with Blood-Brain 
Barrier Opening. Abnormal hyperintense voxels on the T2-weighted MRI (day 0) indicate 
edema in the caudate region. Hypointense voxels on the SWI scans (day 7) suggest 






Qualitative observations of NHP B, O, Ob and N moving around in a contained 
room after domperidone administration revealed two drastically different outcomes. 
During observation sessions when the BBB was not open (the FUS procedure had not 
occurred for at minimum five days), all NHP moved around the room with normal 
locomotion without any signs of neglect. All NHP exhibited normal posture while 
sitting on the floor and had full muscle strength and control while climbing out of and 
into the primate work chair. When domperidone was administered following the FUS 
procedure both NHP N and Ob exhibited signs of hemilateral neglect. These symptoms 
manifested specifically on the side contralateral to the FUS procedure. Neglect 
symptoms included weak muscle tone in both the arm and leg, inability to sit with 
correct posture, and they were only able to rotate their body towards the ipsilateral side 
of the FUS application. The animals would only respond to touch stimuli (stroking of 
the cheek, ear and arm) on the ipsilateral side of the body as the BBB opening. Eyes 
would only track treats towards the ipsilateral side and neck motion was strongly 
biased towards the ipsilateral side as well. Animals were not able to complete hand-
reaching tasks for treats with the contralateral arm, though their ipsilateral arm was 
unaffected. Symptoms subsided 40 minutes after onset. Neither NHP O nor B exhibited 
any neglect symptoms to the IV administration of domperidone following the FUS 
procedures. 
4.5 Discussion 
 While the FUS technique has been shown effective for delivering various drugs 
across the brain for treatment of tumors or to facilitate neuroprotection, the transport of 
neuromodulatory drugs has not been fully explored. Prior longitudinal studies 




reported no long-term changes in behavioral responses to a visuomotor task [143]. 
Results from chapter 3.4 showed the short-term increase in reaction time  on day 0 due 
to the FUS technique, which was why the Haloperidol/FUS+ group was normalized by 
the Saline/FUS+ group to remove these effects of the FUS technique [19]. This allowed 
for the detection of changes in the behavioral responses due to the low dose haloperidol 
reaching the putamen region of the basal ganglia and not the effect of the FUS 
technique.  
 Contrast enhanced T1-weighted MRI scans were acquired 36 hours (day 1) after 
the FUS technique was applied to the putamen region of the NHP. Prior studies 
reported a closing timeline up to three days in NHP depending on the parameters used 
[14]. While both NHP A and Ob still had considerable average volume of BBB openings 
on day 1 (508 mm3 & 192mm3 respectively), NHP N exhibited only small openings (87 
mm3). An acoustic pressure of 400 kPa was utilized with the FUS technique for both 
NHP N and Ob, current work within the Konofagou lab suggests the incident angle of 
the transducer beam with the skull has an effect on the resulting BBB opening volume 
[155]. Here NHP N exhibited smaller incident angles between the transducer beam and 
the skull, which is associated with smaller BBB opening volumes. This could account for 
the discrepancy in the volume of BBB opening between NHP N and Ob as the same 
FUS parameters were utilized, and they are of similar physical stature. As it has been 
shown the BBB volume can close at a rate up to 50 mm3 per day, NHP N may have had 
a smaller volume of opening on day 0 with the majority of it closing by day 1.  
 Although both NHP Ob and N exhibited smaller openings than NHP A, all three 
NHP displayed a significant increase of the difference in the touch error for their 
contralateral hand between the Haloperidol/FUS+ and Haloperidol/FUS- groups. As 
haloperidol is a D2 antagonist, it should bind with the D2 receptors in the putamen 




between the substantia nigra and the striatum [26, 152, 157]. When haloperidol binds 
with these receptors, dopamine is blocked from binding and the indirect pathway is not 
inhibited. This creates a unique scenario where the dopamine continues to bind with the 
direct pathway, promoting motor activity, while the indirect pathway is not inhibited, 
which will impede motor activity. This could account for the increased variability in the 
touch error for the contralateral hand compared to the ipsilateral hand as the signals for 
motor activation could be in conflict, generating more erratic hand responses. 
Both NHP N and Ob showed a significant increase in reaction time to the target 
stimuli. This also agrees with the haloperidol binding to the D2 receptors and inhibiting 
motion. Multiple studies have reported a decrease in locomotion in animal models after 
administering D2 antagonists [158, 159, 160, 161]. This significant increase in reaction 
time for NHP N and Ob also corresponded with an increase with their overall accuracy 
at determining the direction of the dot motion. These results agree with the speed-
accuracy tradeoff paradigm where an increase in reaction time typically correlates with 
responses that are more accurate [136, 142, 163]. The RDM task forces the NHP to 
determine a speed-accuracy trade-off when responding to the stimuli. Results from 
NHP A also agree with this paradigm as NHP A exhibited a significant decrease in 
reaction time between the Haloperidol/FUS+ and Haloperidol/FUS- groups (faster 
responses to the stimuli), corresponding with a decrease in the accuracy of determining 
the coherent direction of the dots.  
While both NHP N and Ob exhibited significant increases in reaction time, NHP 
A showed significant decreases in reaction time to both stimuli regardless of parameters 
(hand, reward value). As NHP A had the largest detected BBB opening, the haloperidol 
may have had effects on the surrounding subcortical nuclei and these additional 
interactions could have generated the increase in motor activity. The location of 




that was outside of the scope of this study [156]. Regardless of the effect, the 
administration of haloperidol after opening the BBB resulted in significant behavioral 
changes in NHP A, signifying successful delivery of the drug. With future experiments, 
the opening area of the BBB should be more precise, allowing better control of where 
the drug is being delivered to in the brain. 
In the murine experiments, a threshold dose of haloperidol administered IP after 
opening the BBB in the caudate-putamen region significantly reduced the motor 
behavioral during the open field test. This agrees with prior studies showing a decrease 
in locomotor activity during open field-testing after administering a dose of haloperidol 
(0.1mg/kg) while the BBB was intact [164]. These results are in agreement with those 
from the behavioral testing for 2 / 3 of the NHP as a significant increase in reaction time 
to the target stimuli was observed. 
The behavioral results from the domperidone experiments are the strongest 
indicators the FUS technique can facilitate drug delivery to targeted regions of the 
brain. Prior studies had shown domperidone as a potent and specific dopamine 
antagonist with in vitro binding studies, but did not affect the striatum due to the 
inability to cross the BBB [145]. This was reflected in the control experiments with 
domperidone where the BBB was intact as no abnormal behavioral effects were 
observed. For both NHP N and Ob, there were distinct behavioral changes after 
domperidone was administered with the BBB opened in their caudate region. The 
results indicate that domperidone was able to cross the open BBB at the caudate region 
and bound strongly with the D2 receptors in the caudate eliciting motor impairment 
through the direct-indirect pathways as discussed prior. The potential hematomas that 
developed in NHP N and O were not related to the delivery of domperidone as NHP O 




potential hematoma, did show strong signs domperidone had been successfully 
delivered. 
4.6 Conclusion 
Current drug delivery methods do not provide region specificity with a non-
invasive procedure, which can lead to unwanted side effects. Other invasive methods 
can incur adverse complications during the procedures. The overall results from the 
behavioral task experiments in chapter 4 illustrate a major benefit for using the FUS 
technique to facilitate targeted drug delivery. Haloperidol is a drug that is currently 
used in clinics for sedation of manic patients and thus it can pass through the BBB freely 
[166]. Here, a threshold dose of haloperidol (0.01mg/kg) that does not have behavioral 
effects when the BBB was intact, elicited changes in the behavioral results after the BBB 
was opened with the FUS technique in both mice and NHP. As many drugs including 
levodopa have the potential for negative side effects, the ability to achieve the same 
effective dose, with a lower administered dose, would greatly lower the chance and 
occurrence of adverse side effects. Domperidone is a large molecule drug that cannot 
cross the BBB, and only after successfully opening the BBB in the caudate region in 
NHP was hemilateral neglect observed due to successful drug delivery. Overall, the 
FUS technique can be safe and effective to non-invasively deliver drugs that have a 
pharmacodynamical effect on the responses of NHP to external stimuli.  
4.7 Contributions 
 In this chapter, the ability of the FUS technique to facilitate targeted drug 
delivery for pharmacodynamical behavioral modulation was investigated. Prior studies 
had shown the technique effective to deliver various neuroactive drugs to the brain for 
the treatment of brain tumors or to promote neurogenesis [21, 22]. Here, the results 




the basal ganglia in both mice and NHP eliciting behavioral effects. Successful delivery 
of domperidone to the caudate in NHP resulted in distinct hemilateral neglect 
contralateral to the brain hemisphere where the FUS procedure was applied. This is 
important as it demonstrates the potential for neuroactive drugs that cannot cross the 
intact BBB due to size to be effective for pharmacodynamical behavioral modulation at 
targeted regions when the BBB is open. Results from the haloperidol studies in mice 
and NHP demonstrated a low dose, here a threshold dosage of haloperidol, can elicit 
similar behavioral effects with an open BBB at the targeted region as a full dose with a 
native BBB. As many current drug therapies incur undesirable side effects, this 
technique can allow for the same effective dose at the target site, with a lower initial 
dosage. The initial lower dosage could potentially reduce adverse side effects. As 
current techniques for drug delivery to the brain are either non-invasive with non-
specific targeting, or region specific and invasive, results in chapter 4 have 
demonstrated the FUS technique can be non-invasive and target specific allowing the 
delivery of both large molecules, and a low dose of neuroactive drugs through the BBB. 
The results discussed here are currently being collected for submission in a peer-
reviewed journal.  
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Specific Aim 3 
Safety and Efficacy of Blood-Brain Barrier Opening via Focused 
Ultrasound with Microbubbles in Alert Non-Human Primates 
Results from specific aims 1 & 2 have demonstrated that the FUS technique is 
effective for opening the BBB in anesthetized NHP. Here in specific aim 3, the potential 
for the FUS technique to open the BBB in fully alert NHP was investigated. Utilizing the 
FUS technique with alert as opposed to anesthetized subjects is ideal for application in 
both the clinic and the laboratory as it removes the possibility of adverse side effects 
from the anesthesia. The behavioral analysis developed in chapters 3 and 4 is once again 
employed to measure the potential side effects of applying the FUS technique while the 
NHP conducted a behavioral task. 
5.1 Abstract 
Focused ultrasound coupled with intravenous microbubbles (FUS) has been 
proven an effective, non-invasive technique to open the blood-brain barrier (BBB) in 
vivo. This study demonstrates that the FUS technique can safely and effectively open the 
BBB at the basal ganglia and thalamus in alert non-human primates (NHP) while they 
perform a behavioral task. The BBB was successfully opened in 86% of cases at the 
targeted brain regions of alert NHP with an average volume of opening 19% larger than 
prior anesthetized FUS procedures. Safety (lack of edema or hemorrhage) of the FUS 
technique was also improved during alert than anesthetized procedures. No 
physiological effects (change in heart rate, motor evoked potentials) were observed 




reaching behavior, but in fact improved performance by decreasing reaction times by 23 
ms, and significantly decreasing touch error by 0.76 mm on average. 
5.2 Introduction and Study Design 
Focused Ultrasound (FUS) combined with systemically administered 
microbubbles (MB) has been shown as an effective, non-invasive technique to open the 
BBB in multiple in vivo models including non-human primates (NHP) [9, 10, 11, 12]. The 
application of the FUS procedure is multifaceted and can be utilized both in the clinical 
and laboratory settings. In the clinic, it can be used to facilitate drug delivery for the 
treatment of neurological diseases or disorders, which currently do not have targeted, 
or non-invasive treatment options [5, 6, 7]. Within the laboratory, the procedure can be 
used for targeted drug delivery eliciting pharmacodynamical modulation during 
behavioral experiments, or evaluation of novel drugs that cannot cross an intact BBB. 
Currently, FUS has only been shown to be safe and effective in anesthetized animal 
models [13, 16, 19]. The anesthesia requirement may not be ideal in a future clinical 
setting. In addition, even in a laboratory setting anesthesia may affect behavioral 
experiment [167, 168]. For the full potential of this technique to be utilized in both the 
clinical and laboratory settings, safe and effective performance in alert subjects needs to 
be shown. 
 One major difference in physiologic conditions when performing the procedure 
on an anesthetized rather than an alert subject lies in the effects of the anesthetic on the 
vascular system. Isoflurane, a common anesthetic used for surgical procedures and 
anesthetized experiments in animals, causes vasodilation and a decrease of vascular 
resistance in cerebral vasculature [169, 170]. Average cerebral capillary diameters of 
NHP are normally around 5 µm, but under isoflurane anesthesia vasodilation occurs 




theory on how FUS causes BBB openings postulates that MB oscillate due to the FUS 
exposure of the vessels. These MB oscillations physically disrupt the endothelial cells 
that comprise the BBB [13, 14, 17, 175]. The two main types of bubble activity reported 
are stable and inertial cavitation [87]. Stable cavitation consists of both harmonic and 
ultraharmonic oscillations of the MB and is the dominant mechanism for BBB opening 
when the MB diameters are similar to the vessel diameter [13]. Inertial cavitation is 
caused when the MB collapse emitting high energy jets, which can damage the 
vasculature and is the dominant mechanism when the MB diameter are smaller than the 
vessel diameter [13, 17, 176]. As the experiments utilizes an average 4-5 µm diameter 
MB, the smaller vessel size during the alert FUS procedures due to the lack of isoflurane 
could change the occurrence of stable and inertial cavitation compared with 
anesthetized procedures. This change in cavitation could translate to a difference in BBB 
opening volume as stable cavitation has been correlated with smaller, safe opening 
volumes while inertial cavitation has been correlated with larger BBB opening volumes 
that have the potential to cause damage (edema, erythrocyte extravasation) [15, 87, 177]. 
The smaller diameter of the vasculature would also increase the overall force the MB 
apply on the endothelial cells from stable oscillations, potentially causing an increase in 
damage to the vasculature [85, 177]. Aside from vessel diameter, cerebral blood flow 
and persistence time of MB in the vasculatures are also affected by the use of isoflurane 
mixed with pure oxygen as an anesthetic [172, 173, 178]. Changes to those parameters 
would affect the dosage of the MB reaching the area targeted by the FUS. Overall, 
isoflurane anesthesia generates unfavorable conditions, the removal of which could 
have an effect on the safety of the tissue in the targeted region and efficacy of the BBB 
opening procedures.  
In this study, the results demonstrate that the FUS technique can be a safe and 




visually guided reaching task to receive fluid rewards. The NHP were head-fixated in a 
primate chair allowing for targeted FUS application while they simultaneously 
completed the behavioral task for fluid reward. The caudate and putamen regions of 
the basal ganglia as well as the thalamus were targeted by the FUS as these regions are 
greatly affected by Parkinson’s disease, which currently does not have a reliable long-
term treatment solution [24, 124]. These regions are also implicated in memory, 
voluntary motor control, goal-directed action and decision making [105, 106, 107]. The 
behavioral task utilized the well-established reward magnitude bias paradigm and 
measured visual perception, motivation and motor function to test the function of the 
targeted regions during application of the FUS technique [119, 120]. A contrast 
enhanced 3D T1-weighted MRI scan was used to verify BBB opening while T2-weighted 
MRI and susceptibility weighted images were used to investigate the safety of the 
technique. The results from the behavioral testing paired with the MRI results 
demonstrate that the FUS procedure for BBB opening can be safe and effective in alert, 
behaving subjects.  
5.3 Methods 
 All NHP procedures described herein were approved by both the Institutional 
Animal Care and Use Committees (IACUC) of Columbia University and the New York 
State Psychiatric Institute. Two adult male Macaca Fascicularis (NHP: Z, A) were used 
for the majority of the experiments (Ages: 14, 18 years old; weights: 5.3, 5.6 kg) and one 
Macaca Mulatta (NHP B, 22 years old, 10.1kg). All husbandry room procedures have 
been previously described in chapter 3.3. Both NHP A & Z underwent IACUC 
approved sterile surgical procedures for a head post implantation allowing head 






FUS Procedure  
 The full specifics on parameters utilized with the FUS technique in this chapter 
are described in chapter 3.3.  
Multiple anesthetized FUS procedures were performed on NHP A and Z before 
conducting the alert procedures (n = 12, n = 4 respectively). An acoustic pressure of 300 
kPa with 4-5µm MB and a 2-minute sonication was utilized for all anesthetized FUS 
procedures. After the FUS procedure, NHP were immediately transported to acquire 
MRI scans (3T, Philips Medical Systems, MA, USA) for verification of BBB opening and 
safety. 
The lightly sedated FUS procedures were only conducted on NHP B. NHP B was 
given a low dose of ketamine (5 mg/kg) and placed into partial stereotactical 
positioning. The top canines were positioned to fit into a custom-made bite bar that 
kept the NHP head steady and in a position similar to that as if it was in full stereotax 
positioning. Once the NHP was positioned the FUS transducer was attached to the 
stereotactic manipulator for targeting of the putamen region. An acoustic pressure of 
300 kPa with 4-5µm MB and a 2-minute sonication was utilized for the lightly sedated 
procedures. MB were administered through a catheter placed in the saphenous vein. 
Heart rate and blood pressure were monitored throughout the procedure. During the 
FUS procedure, the veterinary staff at NYSPI were present to observe if the procedure 
was having any gross negative effects on the body posture of the NHP or on the vitals. 6 
hours after the procedure had finished, MRI scans were acquired to verify BBB opening 




The setup of the alert experiment can be seen in Figure 28. Initially the NHP were 
lightly sedated with ketamine (0.3 ml) for the placement of a catheter in the saphenous 
vein for IV delivery of the MB. NHP were then placed into the primate chair and head 
fixated. A pulse oximeter clip was placed on the ear ipsilateral to the placement of the 
transducer. The two positive EMG leads were placed on the temporalis muscle 
contralateral to the transducer with the ground placement ipsilateral to the transducer 
(MP150 Data Acquisition system, BIOPAC Systems Inc., CA, USA). The transducer was 
then attached to the stereotactic manipulator for targeting of the focal region and the 
NHP was allowed to begin the behavioral task within a light and soundproof testing 
booth. Animals were allowed to work for an hour before beginning the FUS procedure. 
The FUS was applied at the onset of MB injection, which was through surgical tubing 
attached to the catheter that came out from the work booth. This allowed the NHP to 
continue to work uninterrupted throughout the application of the FUS procedure. An 
acoustic pressure of 300 kPa with 4-5µm MB and a 2-minute sonication was utilized for 
all alert FUS procedures. After the FUS procedure finished NHP were allowed to work 
until satiated. MRI scans were acquired for each NHP 5 hours after the animal 





Figure 28: Alert Focused Ultrasound Behavioral Setup. The NHP was placed into a primate 
work chair and was head fixated. This position allows free movement of their arms to respond 
with the ipsilateral arm as the stimuli from the behavioral task displayed on the touch monitor. 
The transducer, EMG leads and pulse oximeter were positioned on the scalp of the NHP. The 
experiment was run external to the booth allowing the NHP to complete the behavioral task 
unaware when the FUS technique was applied.  
MRI Analysis 
MRI scans for the aforementioned FUS procedures were as follows: T2-weighted 
and Susceptibility Weighted (SWI) scans were acquired to verify the safety of the FUS 
procedure. Gadodiamide (Omniscan®, 573.66 DA, GE, Healthcare, Princeton, NY, USA) 
was injected before acquiring contrast enhanced 3D T1-weighted images to verify BBB 
opening. Gadodiamide was selected as a contrast agent as it cannot cross the intact BBB. 
Full specifications on the MRI acquisition have been previously discussed in chapter 





 Behavioral control data were acquired with and without ketamine on separate 
days. For days when ketamine was administered, a dose of 0.3 ml ketamine was 
injected IM before testing to stay consistent with days when an IV catheter needed to be 
inserted for the FUS procedure. Non-ketamine control days were used to verify the 
small dose of ketamine administered during the FUS procedure days did have an effect 
on the behavioral results. Thus, the ketamine control days were utilized to find a 
regression curve over time to reduce the effects of ketamine in the experimental days 
(Figure 29 B). As mentioned previously NHP were placed in a primate chair for head 
fixation and positioning of the transducer. The transducer was not utilized on days 
when the FUS procedure did not occur, but was still positioned on control days to 
create consistent testing conditions for the NHP. Both NHP were trained to respond to 
visual stimuli presented on a 20-inch color LCD touch panel display (NEC 2010X with 
3M SC4 touch controller). The task was designed to employ the well-established reward 
magnitude bias (RMB) paradigm [77, 120]. This task tested reaction time (RT), touch 
error (TE), and motivation. Stimuli were presented randomly as either horizontal or 
vertical yellow bars of equal pixel area and intensity indicating high and low reward 
respectively (5:1 reward bias). An initial cue was presented randomly on either the left 
or right side of the screen. Once the NHP touched the cue, a secondary target of same 
shape, pixel area and intensity appeared. After the NHP touched the target, the water 
reward was given based on the magnitude indicated by the cue and the target. RT to the 
cue and target was determined as the onset of the stimuli to the first touch registered by 
the touch panel. TE to the cue and target was determined by the distance between the 





Figure 29: Raw Reaction Time Data for Alert Behavioral Testing. Reaction times for individual 
trials as a function of time during the experiment. For (A) and (B) magenta dots indicate 
individual data points and the black line is the linear regression fit. A) shows the control data 
collected on days when ketamine was not administered. B) shows the control data collected on 
days when ketamine was administered to mimic the parameters used on experimental days. 
The regression fit for the ketamine control data was used to normalize the experimental data to 
remove the effects of ketamine on the behavioral results during experimental days. C) shows 
the normalized experimental data. Red dots indicate trials completed before applying the FUS 
technique, blue indicates trials completed during the FUS technique and green indicates trials 
completed after applying the FUS technique. 
Data Analysis 
 T2-weighted and SWI scans were stereotactically aligned using fsl to determine if 
there was any hyper- or hypointense voxels in the targeted regions [126]. Post contrast 
T1-weighted scans were also stereotactically aligned and post processed to determine 




chapter 3.3. Significance between the volume of opening data from the alert and 
anesthetized FUS procedures was determined with a Wilcoxon rank-sum test (p < 0.05). 
 Passive cavitation detection (PCD) signals were acquired during all FUS 
procedures. The full cavitation signal was processed by frequency as harmonic, 
ultraharmonic and broadband emissions of the MB. Stable cavitation dose was 
quantified as the energy output from harmonic and ultraharmonic emissions, while 
inertial cavitation was quantified from the energy of the broadband emissions. 
Significance between the PCD data from the alert and anesthetized FUS procedures was 
determined with a student t-test (p < 0.05). 
 Both the raw EMG and heart rate data were initially processed using the same 
pipeline. Data was recorded during experiments at 2000 Hz. Signals were normalized 
by the mean to remove machine bias before being passed through a band-pass filter 
(100-300 Hz) to remove electrical noise and heartrate artifacts [179]. Finally, the absolute 
value of the signal was taken for full wave rectification. A sliding window step 
detection algorithm was applied to locate muscle activity. Amplitudes of the detected 
muscle activity during application of the FUS technique were compared to control 
signals of the NHP drinking water and moving its jaw. Amplitudes within a maximum 
threshold recorded during the control were counted to be voluntary movement by the 
NHP. A peak finding function was used with the heart rate data to determine beats per 
minute (BPM). BPM was determined for three groups, pre, during and after the FUS 
procedure. A 1-way ANOVA was used to determine if there was significant variation in 
heart rate during the FUS procedure (p < 0.05).  
Behavioral data was divided by ketamine control days (days when no FUS 
procedure had occurred for at a minimum 5 days) and experimental days (days when 




to find normalization curves for both reaction time (RT) and touch error (TE) data to 
reduce the effects of the ketamine from the experimental days (Figure 29 B). Data from 
the experimental days were divided into three groups, pre sonication, during sonication 
and post sonication. For analysis of the experimental data, trials only occurring 30 
minutes before and after the sonication were selected. These trials were then 
normalized with the curve found with the ketamine control data. Variation between 
each group was evaluated with 1-way ANOVAs (p < 0.05). Averages were compared 
across group for significant differences using a student t-test (p < 0.05). Data was also 
subdivided by reward magnitude (high and low). The average differences (high – low) 




Initial trials of the FUS procedure on a lightly sedated (single 5mg/kg dose of 
ketamine) NHP (subject B) did not elicit any autonomic changes. Heart rate and blood 
pressure remained consistent throughout the procedure (136 beats per minute, 68 mean 
arterial pressure). These vital recordings agree with the results from the monitoring of 
the vitals during the longitudinal study in chapter 3. No sudden limb, jaw or eye 
movement, nor pupil dilations were observed by researchers or the observing NYSPI 
veterinary staff. After the procedure, NHP B recovered normally from light anesthesia 
and returned to routine activities (playing, eating, and drinking). T2-weighted MRI and 
susceptibility weighted image (SWI) scans did not show any abnormal hyper- or 
hypointense voxels in the targeted regions signifying no edema or hemorrhage had 




Having verified the preliminary safety of the procedure in a lightly sedated 
NHP, the FUS technique was applied to alert NHP. The full setup for the alert FUS 
technique along with behavioral testing can be seen in Figure 28. As with the lightly 
sedated experiment, application of the FUS technique did not cause any macroscopic 
motor effects (sudden limb, body or eye movement) nor did it elicit a pain grimace for 
either NHP, regardless of the targeted brain region. Heart rate remained consistent 
throughout the FUS technique and within the normal range for fascicularis macaques 
(NHP A: 152.4 ±1.2 BPM, NHP Z: 179 ±8.9 BPM). The larger variation in the heartrate 
for NHP Z arose from motion artifacts in the SpO2 signal as he was generally more 
active while he worked. Neither of the NHP exhibited an abrupt change in heartrate 
with the onset or during the application of the FUS technique. EMG recordings on the 
temporalis muscle only detected normal jaw and mouth movements (licking reward 
tube, smacking lips) during the procedures (Figure 30). There were no abnormal or 
large EMG signals detected either during or after the FUS procedure that surpassed the 





Figure 30: EMG Recordings. EMG signals were recorded from the temporal muscle 
contralateral to the FUS application. The grey region denotes when either the control (A) or the 
full sonication (B) with the transducer was being applied. Red dashed vertical lines indicate 
detected muscle activation. The horizontal green bar indicates the maximum signal recorded 
during the control period (indicated by the green dot) and subsequently used as the threshold 
to detect abnormal or large signals that occurred during the application of the FUS technique. 
Only recordings from NHP Z are shown, but NHP A showed similar responses. There was no 




The majority of the T2-weighted and SWI scans did not show abnormal hyper- or 
hypointense voxels for both NHP Z and A (Figure 31 A). NHP A exhibited one case of 
unusual hyperintense voxels on a T2-weighted MRI scan after an alert FUS procedure 
on day 0 (i.e. the day of the procedure, Figure 31 B). The hyperintense voxels were not 
present on day 7, which suggests the potential for transient edema in NHP A when 
targeting the caudate. No hyper- or hypointense voxels were detected in the region of 
possible edema on SWI scans on either day 0 or day 7. These results show that the FUS 
technique has some probability to cause a reversible edema without 
microhemorrhaging in alert NHP. By comparison, during 12 anesthetized procedures, 
NHP A had 3 cases of hyperintense voxels on the T2-weighted scans on day 0. Similar 
to the alert experiments, the hyperintense voxels were not present on day 7. Histological 





Figure 31: MRI Safety Verification in Alert Non-Human Primates. T2-weighted and SWI 
sequences were acquired to verify the safety of the alert FUS procedures. A) shows typical cases 
of both T2-weighted and SWI scans of the targeted regions. There were no abnormal hyper or 
hypointense voxels present in any of the targeted regions (caudate, putamen or thalamus). B) 
shows the one case for NHP A when there were hyperintense voxels in the targeted region in 
the T2-weighted scan, denoted by the red dashed circle. This area of hyperintense voxels could 
indicate the presence of edema. By day 7 the hyperintense voxels were absent. Neither on day 0 






Post contrast T1-weighted MRI sequences verified BBB opening for the majority 
of the alert FUS procedures on NHP A & Z. Typical cases of BBB opening are indicated 
by a transparent red color map  overlaid on the T1-weighted MRI scans shown in 
Figure 32. The contrast enhanced areas cover the targeted putamen region for NHP A 
and NHP Z. Successful BBB openings were obtained in 6/7 (NHP A) and 7/8 (NHP Z) 
alert FUS procedures. Figure 33 shows NHP A exhibiting larger BBB openings on 
average (526 ± 220 mm3) than NHP Z (450 ± 97 mm3) after alert FUS procedures. Success 
rate of BBB opening and the average of the BBB opening volumes per location and NHP 
are listed in Table 9. Both NHP showed on average 19% larger BBB opening volumes 
for the alert compared to anesthetized FUS procedures. Only NHP Z exhibited a 
significant increase in BBB opening volume for the alert compared to anesthetized 
procedures (WRS test, p < 0.05). Figure 34 shows a non-significant increase in the 
detected stable cavitation dose from the passive cavitation detection (PCD) for the alert 
procedures over the anesthetized procedures for both NHP (WRS test, p > 0.05). There 
was also a non-significant decrease in inertial cavitation dose between the alert and 
anesthetized procedures (t-test, p > 0.05). 
Table 9: BBB opening per location for each NHP. 




Caudate N/A 369 ± 225 mm3 
(n = 2/3) 
N/A N/A 
Putamen 335 ± 150 mm3 
(n = 3/3) 
657 ± 203 mm3 
(n = 3/3) 
270 ± 75 mm3 
(n = 4/4) 
500 ± 197 mm3 
(n = 9/12) 
Thalamus 462 ± 110 mm3 
(n = 4/5) 
442 mm3 
(n = 1/1) 
N/A  
 Averages volumes and standard deviations here reflect only when BBB opening was 





Figure 32: Blood-Brain Barrier Opening Verification in Alert Non-Human Primates. Contrast 
enhanced T1- weighted sequences were acquired to verify the opening of the BBB. The 
transparent red regions indicate the BBB opening volume. Typical cases of BBB opening for the 
alert FUS procedures are in the left column, while typical results from anesthetized FUS 





Figure 33: Alert vs Anesthetized Blood-Brain Barrier Volume. The average volume of BBB 
opening from the alert and anesthetized FUS technique are compared per animal. The mean is 
indicated with a blue horizontal bar while the standard deviation is indicated by a red vertical 
bar. The black circles are individual BBB opening cases. The dashed bars indicate anesthetized 
experiments. Both NHP had a non-significant increase in the volume of BBB opening for alert 
FUS procedures over anesthetized (2-sided WRS test, p = 0.012). 
 
Figure 34: Cavitation Doses for Alert and Anesthetized Non-Human Primates.  During both 
the alert and anesthetized FUS procedures the passive cavitation detection recorded the signals 




dosage and 95% confidence interval of the mean for alert FUS procedures while red indicates 
average cavitation dosage 95% confidence interval of the mean for anesthetized FUS 
procedures. A) shows the average harmonic cavitation doses while (B) shows the average 
inertial cavitation dosages. For both NHP there was a non-significant increase in harmonic 
cavitation doses between the alert and the anesthetized FUS procedures. The inverse occurred 
with the inertial cavitation dose with smaller doses detected during the alert compared to the 
anesthetized FUS procedures. 
Behavioral Results: 
To determine if the FUS procedure affected visuomotor behavior or motivation, 
the NHP were trained to perform a visually guided reaching task with differential 
reward. The RMB task completed by the NHP during the FUS technique was utilized as 
a more sensitive evaluation of the potential side effects of the technique on the central 
nervous system of the NHP. The behavioral variables recorded were reaction time (RT) 
and touch error (TE). Individual responses to the task for the control and experimental 
days are shown in Figure 29. On days when the FUS technique was administered, the 
NHP were given a low dose of ketamine for placement of the IV catheter prior to 
behavioral testing. This resulted in a slight anesthetic effect, which was observed in the 
behavioral results. The control data after ketamine shows elevated RTs at the beginning 
of each day’s behavioral testing that decrease over the duration of the session (Figure 29 
B). This decrease was not observed on days when the animal performed the task 
without any prior ketamine (Figure 29 A). Thus, this decrease along the entire duration 
of the behavioral task can be attributed to the lingering effects of the ketamine. As a 
control, on some days, the same low dose of ketamine used when placing the IV 
catheter was administered prior to behavioral testing, but the FUS technique was 
applied. Linear regression was performed on the ketamine control data and used to 




technique was applied, Figure 29 C). This normalization was performed with for RT 
and TE.  
On each trial of the behavioral task, the NHP first touched a cue stimulus and 
then touched a target presented four cm away from the cue. One benchmark to 
determine if the FUS procedure had an effect on the NHP while they conducted the 
behavioral task was to evaluate their reaction times (RT) to the cue and target stimuli. 
The average RT to the cue and target are shown in Figure 35 A. NHP A did not show 
significant variation in the means between groups, nor significant difference between 
the pre- and during or post- and during groups (1-way ANOVA, student’s t-test, p > 
0.05). NHP Z did not show any significant difference across groups for the cue stimulus, 
but did show a significant increase between the pre-and during groups to the target (1-
way ANOVA, student’s t-test, p < 0.01). This increase persisted into the post-sonication 
period, which was not significantly different from the during group (student’s t-test, p > 
0.05). Overall, in three out of the four cases there was a slight decrease in reaction time 
after the application of the FUS procedure.  
While variations in RT assess the speed of the visuomotor response, touch error 
(TE) can be used to detect variations in spatial accuracy of the reaching movement [180]. 
Touch error was determined as the distance between the center of the stimulus (cue or 
target) and the first point where the NHP contacted the touchscreen monitor. Figure 35 
B shows that for NHP A there was a significant decrease in TE to the cue between the 
pre- and during groups, as well as between pre- and post groups (student’s t-test, p < 
0.001). This significant decrease in TE was also observed with the response of NHP A to 
the target stimuli. Similarly, there was a significant decrease in TE for NHP Z 





Figure 35: Behavioral Results after Focused Ultrasound Procedures in Alert Non-Human 
Primates. The responses to the behavioral task were measured in reaction time and touch error. 




FUS procedure). The horizontal blue bar indicates the average reaction time for each group 
while the red vertical bar indicates the standard error. There was a small non-significant 
decrease across the groups for both NHP reacting to the cue (2-sided student’s t-test, p > 0.05). 
NHP A exhibits this decrease in reaction time across groups when responding to the target, but 
NHP Z shows a significant increase in reaction time to the target (2-sided student’s t-test, p = 
0.013). B) Shows the average touch error for each group. Blue horizontal bars indicate the 
average touch error while red vertical bars indicate the standard error. For both NHP there was 
a significant decrease in touch error between the pre- and the during group in response to the 
cue (2-sided student’s t-test, p < 0.01). Only NHP A also exhibited a significant difference in 
touch error between the pre- and during groups to the target. C) Shows the difference in 
reaction time between the high and the low reward. Horizontal blue bars indicate the average 
difference in reaction time (high-low) while the red vertical bars indicate standard error. 
Our behavioral task included a reward bias; on some trials, the NHP received 5 
drops of water as a reward for correct performance. On other trials, the reward was 1 
drop. A visual cue (the orientation of the cue and target stimuli) signaled the reward 
size. The reward value for each trial was random so the NHP could not predict which 
stimuli would appear next. Once the cue appeared, it informed the NHP as to the 
reward size. NHP will often respond faster and more accurately on trials with larger 
rewards [136, 142]. Hence, the reward bias can help to determine if motivation was 
affected by the FUS procedure. For both NHP there was no significant variation across 
all groups nor a significant change in RT difference between individual groups (1-way 
ANOVA, student’s t-test, p > 0.05, Figure 35 C). This behavioral task has been 
previously employed in our lab and successfully elicited specific motivational responses 
to the high/low reward, but these results indicate that this did not occur during these 
experiments [19]. This lack of reward bias was also absent for the control data sets, and 






In this study, it was demonstrated that the FUS technique is a safe and effective 
procedure on alert NHP using MRI verification, physiological recordings and 
behavioral assessment. An 86% success rate for opening the BBB at the targeted regions 
was achieved and the volume of the BBB openings in alert NHP were 19% larger than 
openings achieved with anesthetized FUS procedures in the same NHP. The increase in 
BBB opening volume could be due to several factors. For example, the dosage of MB 
that reached the target area could have been larger during alert than anesthetized 
experiments. As oxygen mixed with 1.1-1.5% isoflurane was used for anesthesia during 
the anesthetized experiments, the MB would have a shorter circulation time as prior 
studies have shown that oxygen increases the decay rate of MB in the bloodstream by 
approximately a factor of three [178]. This would decrease the dosage of MB reaching 
the target site, and also decrease the overall PCD signal detected during the 
anesthetized procedures. An increase in stable cavitation dosage in alert subjects was 
not detected, which could be attributed to the higher MB dose. However, a decrease in 
the inertial cavitation dosage was observed. This finding agrees with prior studies 
where the diameter of the vessel has an effect on the behavior of the MB inside the focal 
area of the transducer. When the vessel diameter is larger than the MB size, inertial 
cavitation is the dominant mechanism for BBB opening, and conversely when the 
diameter of the vessel and the MB size are comparable, stable cavitation becomes the 
dominant mechanism [84]. As no isoflurane was used during the alert FUS procedures, 
the vessels would not have been dilated, retaining their average size of 5 µm, which is 
comparable to the 4-5 µm diameter MB used for the experiments [169]. This would 
support the results showing an increased stable cavitation dosage and a decreased 
inertial cavitation dosage during the alert compared to the anesthetized FUS 




cerebral blood flow (CBF). High doses of isoflurane have been correlated with higher 
CBF, which would produce larger PCD signals as more MB would be passing through 
the focal region for each ultrasound pulse. This increase in CBF was previously 
observed at isoflurane doses > 1.6% [173]. For the anesthetized experiments, NHP were 
only initially dosed with 2% isoflurane for placement into the stereotax before being 
reduced to 1.1-1.5% for the duration of the experiment. Thus in the previous 
anesthetized FUS procedures, the level of isoflurane needed to increase the CBF may 
not have been reached. The increase in stable cavitation dosage during FUS procedures 
with alert NHP could be attributed to a larger dose of MB, as circulation time was not 
reduced, as well as smaller vessel diameters that were comparable to MB diameter.  
BBB opening was achieved safely (as assessed by T2-weighted MRI and SWI 
scans) for the majority (13/15) of the alert experiments with only one case of potential 
edema (out of 7 procedures) in NHP A, which resolved within a week. This was a 
decrease in the occurrence of hyperintense voxels appearing in the targeted region for 
NHP A compared to anesthetized experiments when it occurred 3 times in 12 
procedures. These findings are concordant with the decrease in inertial cavitation 
dosage recorded during the alert FUS procedures. Prior studies have shown a 
correlation between inertial cavitation with edema and red blood cell extravasation [16, 
13]. The inertial cavitation dosage was lower in the alert FUS procedures, which 
explains the less frequent occurrence of edema. Overall, the results show that the alert 
FUS procedure elicited fewer cases of potential edema on average than prior 
anesthetized studies.  
Importantly, the procedure did not elicit any gross negative physiological 
reactions (ballistic motor activity, pain grimace) while the NHP were completing the 
behavioral task. Their heart rate remained consistent before, during and after the 




in the local area of the transducer during the procedure. This lack of abnormal EMG 
signals shows that the FUS technique does not elicit muscle activity in the local area of 
application. 
The FUS procedure was administered during ongoing performance of a self-
paced visuomotor reacting task. There was no disruption in the NHP’s behavior once 
the task had begun. The NHP continued to initiate trials at the same rate before, during 
and after FUS administration. A small, non-significant decrease in reaction time to the 
cue stimuli was observed after the application of the FUS technique. The procedure also 
significantly decreased touch error by reducing the average touch error between the 
pre- and during group for both the cue and target stimuli for NHP A. Another FUS-
based technique, transcranial-FUS (tFUS), is currently being investigated as an 
alternative to transcranial magnetic stimulation and has been shown to successfully 
elicit neuromodulation in partially sedate and alert NHP and humans [31, 32]. Although 
tFUS utilizes different transducer parameters (pressure, pulse repetition frequency, 
duration of sonication) than the FUS BBB opening technique, the results show the FUS 
technique targeting the basal ganglia and thalamus has the potential for small beneficial 
effects improving the accuracy of the NHP selecting the targets present on the screen. 
5.6 Conclusions 
This initial feasibility and safety study verifies the FUS technique was slightly 
safer and more effective than prior anesthetized experiments with a potential beneficial 
decrease in reaction time and an increase in tactile accuracy. Results obtained agree 
with the literature on how modifying the parameters of the FUS technique affect the 
safety and success of the procedure. This technique will be continued to be investigated 






 Results presented here in chapter 5 continue to demonstrate the FUS technique 
could be a powerful tool in both the clinic and the laboratory. Traditionally the 
technique had only been conducted in anesthetized in vivo models, but here for the first 
time the results demonstrate the technique can be safe and effective in fully alert NHP. 
Moreover, the results show that the occurrence of BBB opening was safer and the 
average volume of BBB opening larger than in anesthetized models. During the 
application of the FUS technique NHP were not only able to continually respond to a 
visuomotor task presented to them, their responses improved. Average reaction time 
decreased while their touch error significantly decreased. The behavioral results 
combined with the MRI data validate the FUS technique is safe and effective in alert 
NHP.   
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 The current clinical techniques for drug delivery through the blood-brain barrier 
(BBB) can be effective for treating specific neurological diseases. Unfortunately, none of 
those approved techniques facilitates drug delivery with a method that is both non-
invasive and brain target specific. Focused ultrasound with intravenous microbubbles 
(FUS) fills this vacancy as it transiently and non-invasively opens the BBB accurately at 
specific targets in the brain. While this technique has been investigated for fifteen years, 
it is now reaching the pre-clinical transition period before human testing begins. 
 The work presented in this thesis focused on validating the safety and efficacy of 
the FUS technique for both opening the BBB in NHP, and delivering drugs generating 
pharmacodynamical behavior effects. The majority of the experiments conducted here 
were with NHP, an ideal subject for pre-clinical testing. Results from the initial 
longitudinal study verified the FUS technique was both a safe and effective method to 
open the BBB at specific brain regions in the NHP without adverse long-term effects. 
The technique was then demonstrated to be effective in facilitating drug delivery, both 
large molecule or a low dose, to modulate behavior of the NHP. Finally, for the first 
time, the results illustrated that the FUS technique can be applied to alert NHP inducing 
safe BBB opening without macroscopic physiological changes.  
The first section of this thesis explored the safety of the FUS technique through a 
longitudinal study spanning 4-20 months in four NHP. Results indicated there were no 
long-term degenerative effects of repeated application of the FUS technique targeting 




cases of potential edema were only transient and not persistent a week after occurrence. 
Behavioral testing indicated the FUS technique may have caused an increase in the 
reaction time on day 0 (the day when the FUS technique was performed), but this shift 
of behavioral responses returned to baseline within five days. Results in this section 
were important for validating the application of the FUS technique as a long-term 
therapeutic procedure. This technique may be used as an outpatient procedure for 
regular (i.e. biannually) drug delivery to specific brain regions to treat chronic 
neurological diseases such as Parkinson’s or Alzheimer’s. Here the results indicated 
that repeated targeting of a specific brain region does not elicit permanent structural or 
neurological changes, which is the first step in validating this technique for long-term 
clinical applications.  
The second part of the thesis investigated utilizing the FUS technique for drug 
delivery to the basal ganglia. Domperidone was successfully delivered to the caudate in 
two NHP while haloperidol was successfully delivered to the putamen in NHP and the 
caudate-putamen in mice. As both drugs selected were D2 receptor antagonists, their 
effects were recorded during visuomotor (NHP) and simple motor (mice) behavioral 
tasks. Domperidone was shown to cause severe hemilateral neglect in 2/4 NHP on the 
side contralateral to the FUS procedure. This neglect persisted on average 40 minutes 
after onset and was not correlated with any permanent abnormal safety results. The 
successful delivery of domperidone demonstrates the FUS technique can deliver large 
molecule drugs through the BBB allowing for pharmacodynamical behavioral 
modulation. Haloperidol was also successfully delivered to the putamen region in NHP 
where it caused significant changes in the reaction time to the visually presented 
stimuli. Results from the NHP-haloperidol study illustrate the administration of a drug 
at a low dose while the BBB is opened at the intended region of drug-brain interaction 




Successful treatment with lower drug doses could alleviate adverse side effects with 
current drug therapies.  
The final section of this thesis focused on a major hurdle of the pre-clinical 
transition period for the FUS technique of validating the procedure as a safe and 
effective procedure in alert subjects. The technique was applied to the basal ganglia and 
thalamus region of two alert NHP while they completed a visuomotor behavioral task. 
As the FUS procedures were conducted without isoflurane, there were no vasodilatory 
effects as seen with prior anesthetized procedures. This resulted in larger BBB opening 
sizes, as well as an increase in stable cavitation dose, while decreasing the inertial 
cavitation dose. This change in cavitation dose produced less cases of potential edema 
for the alert FUS procedures compared to the anesthetized procedures using the same 
FUS parameters. The FUS technique did not elicit any macroscopic abnormal behavioral 
effects. Conversely, it slightly improved reaction time and significantly reduced touch 
error during the FUS procedure. Results demonstrate that the FUS technique can be 
safely applied to alert subjects without the potential of negative side effects.  
In conclusion, the work presented here continues to validate the FUS technique 
as a safe and effective technique for transient BBB opening in NHP. Safety and efficacy 
were demonstrated for long-term application in anesthetized subjects. The technique 
was also shown as an effective method for facilitating both large molecule, or low dose 
drug delivery allowing pharmacodynamical modulation of responses to behavioral 
tasks in both NHP and mice. Finally, both the safety and efficacy of the FUS technique 
were verified in alert subjects. Continued research utilizing the FUS technique will 
prove the technique to be a powerful tool assisting in the treatment of neurological 





6.2  Future work 
 Building from the findings presented here, the FUS technique can be used for 
drug delivery in alert NHP. This allows for targeted, non-invasive drug delivery during 
behavioral testing. Specifically, this technique could be coupled with electrophysiology 
studies investigating the neural activity of selected regions in response to the behavioral 
task.  
 Other potential investigations within the laboratory include utilizing the FUS 
technique to deliver drugs to a 6-hydroxdopamine (6-OHDA) NHP PD model. Targeted 
delivery of dopamine to affected areas of the 6-OHDA NHP while completing a 
behavioral task should demonstrate recovery of neurobehavioral deficits induced by the 
6-OHDA. This would be a pivotal study demonstrating the FUS technique is well suited 
to facilitate treatment of diseases such as Parkinson’s disease. 
 Building on the aforementioned project, the technique could be applied to open 
the BBB at the basal ganglia and substantia nigra in Parkinson’s patients to deliver 
dopamine or other currently available drugs. Results from chapter 4 in this thesis 
demonstrate the successful delivery of large molecule drugs, thus the delivery of 
dopamine should be achievable in patients. Treatment of PD using dopamine instead of 
levodopa would reduce the potential for the development of adverse side effects such 
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